Abstract
Fluorinated carbohydrates are important tools for understanding the deregulation of metabolic fluxes and pathways. Fluorinating specific positions within the sugar scaffold can lead to enhanced metabolic stability and subsequent metabolic trapping in cells. This principle has, however, never been applied to study the metabolism of the rare sugars of the pentose phosphate pathway (PPP). In this study, two fluorinated derivatives of d‐sedoheptulose were designed and synthesized: 4‐deoxy‐4‐fluoro‐d‐sedoheptulose (4DFS) and 3‐deoxy‐3‐fluoro‐d‐sedoheptulose (3DFS). Both sugars are taken up by human fibroblasts but only 4DFS is phosphorylated. Fluorination of d‐sedoheptulose at C‐4 effectively halts the enzymatic degradation by transaldolase and transketolase. 4DFS thus has a high potential as a new PPP imaging probe based on the principle of metabolic trapping. Therefore, the synthesis of potential radiolabeling precursors for 4DFS for future radiofluorinations with fluorine‐18 is presented.
Keywords: fluorinated carbohydrates, metabolic trapping, pentose phosphate pathway, rare sugars, d-sedoheptulose
Synthesis of 4‐deoxy‐4‐fluorosedoheptulose (4DFS) and 3‐deoxy‐3‐fluorosedoheptulose (3DFS) as well as of suitable precursors for the synthesis of their [18F]‐analogues is described. First biochemical investigations show that 4DFS is taken up by human fibroblasts and phosphorylated (giving 4DFS7P) but not further metabolized by transaldolase or transketolase. Thus, 4DFS has a high potential as new pentose phosphate pathway imaging probe.
Introduction
The pentose phosphate pathway (PPP) is a branch of carbohydrate metabolism that shares several common intermediates with glycolysis. It provides cells with the required reducing agents (NADPH) for redox regulation and lipid biosynthesis and is the sole source of ribose‐5‐phosphate (R5P) for de novo nucleotide biosynthesis. [1] It consists of an irreversible oxidative (oxPPP) phase, and a highly complex network of reversible reactions forming a non‐oxidative (non‐oxPPP) phase. During the non‐oxPPP, carbon scrambling events between monosaccharides of different chain length (C3, C4, C5, C6 and C7 sugars) [2] take place to ultimately generate ribose‐5‐phosphate (R5P) or revert excessive pentose phosphates back to glycolytic intermediates. Apart from their role during R5P formation, these rare sugar phosphates were long considered to be otherwise insignificant metabolic intermediates. The recent discovery of specialized kinases for d‐ribulose, d‐xylulose and d‐sedoheptulose[ 3 , 4 , 5 , 6 , 7 ] suggests that these rare sugars can be directly shuffled into primary carbohydrate metabolism. This also raises questions on the extent to which cells consume and rely on these rare sugars7 to directly modulate the carbon flux between the non‐oxPPP and glycolysis by influencing the stoichiometry of the involved metabolites.7 The respective kinases might even be selectively regulated in areas with elevated oxidative stress or high need for R5P during cell proliferation.
This is of particular interest as elevated flux rates towards the PPP and altered PPP enzyme expression levels are often associated with severe pathologies, such as cancer.[ 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 ] Thus, highly sensitive methods are needed to determine flux rates towards the PPP.
Inspired by the mode of action of 2‐deoxy‐2‐[18F]fluoro‐glucose ([18F]FDG), [19] which is the most widely used [20] positron emission tomography (PET) tracer for glucose‐dependent energy consumption imaging, we designed a possible strategy to visualize areas of elevated carbohydrate metabolism via the PPP based on two deoxy‐fluorinated analogs of d‐sedoheptulose (Scheme 2A). Replacing the stable isotope fluorine‐19 with the positron emitting radionuclide fluorine‐18, opens up the possibility to study carbohydrate metabolism in a highly sensitive way in vivo by PET imaging. [21] [18F]FDG is taken up by cells via glucose transporters, phosphorylated by hexokinase but cannot be broken down by glycolysis (Scheme 1). Hence, [18F]FDG‐6‐phosphate (FDG6P) accumulates inside cells with a high glucose turnover and allows the visualization of altered metabolic rates of glucose. We want to apply this principle to a different sugar‐phosphate that plays a vital role for the human metabolism: sedoheptulose‐7‐phosphate.
Results and Discussion
Design of Target Compounds
Based on the discovery of a specific sedoheptulose kinase (SHPK), [5] we hypothesized that deoxy‐fluorinated d‐sedoheptulose derivatives, such as 4‐deoxy‐4‐fluoro‐d‐sedoheptulose (4DFS) and 3‐deoxy‐3‐fluoro‐d‐sedoheptulose (3DFS) could be used to identify areas with an upregulation of the non‐oxPPP in a similar way to glucose metabolism imaging with FDG. S7P can be metabolized by two enzymes: transaldolase (TALDO1) and transketolase (TKT, scheme 2B). While TALDO1 cleaves the C−C bond between carbon 3 and 4 of S7P before ultimately oxidizing C‐4 and forming erythrose‐4‐phosphate (E4P), TKT removes a C2‐unit of S7P by breaking the C−C bond between carbon 2 and 3 and then oxidizes C‐3 to form R5P. We assume that 4DFS and 3DFS, if accepted by SHPK, would form the respective fluorinated sugar‐phosphates and that the C−F bond would then block the attack by either TALDO1 (in case of 4DFS) or TKT (in case of 3DFS). Thus, they should finally be metabolically trapped inside cells. Support for this hypothesis comes from Evdokimov et al. who found that 2‐deoxy‐2‐fluoro‐d‐ribose‐5‐phosphate is converted by TKT in a similar way as its natural substrate (R5P) to give 4‐deoxy‐4‐fluoro‐d‐sedoheptulose‐7‐phosphate (4DFS7P). [22] The latter is, however, not accepted as a substrate by TALDO1 and thereby metabolically trapped in vivo. The corresponding fluorine‐18 labeled compounds, [ 18 F]4DFS and [ 18 F]3DFS, could be used as PET tracers to identify areas of elevated carbohydrate metabolism via the PPP and hint at pathology‐related deregulations. Thus, we aimed at the synthesis of 4DFS and 3DFS as well as of suitable precursors for the synthesis of their radiolabeled counterparts.
Synthesis of deoxyfluorinated sugars
We set out to probe our hypothesis by first synthesizing 4‐deoxy‐4‐fluoro‐d‐sedoheptulose (4DFS) and 3‐deoxy‐3‐fluoro‐d‐sedoheptulose (3DFS). Recent examples of de novo synthetic strategies for the synthesis of fluorinated carbohydrate scaffolds led to impressive results regarding the obtained level of stereocontrol.[ 23 , 24 ] However, we did not choose a de novo synthetic approach for the synthesis of 4DFS as Yan et. al already showed that both manno and allo configured sugar epoxides can be used for fluorinations. This makes both the desired fluorinated altro configured pyranose core structures of 3DFS and 4DFS accessible from the same stable and commercially available starting material within 3 steps. [25] Thus, we aimed to combine this epoxide opening approach with the C1‐elongation method developed by Waschke et al. for synthesizing these heptuloses. [26]
Commercially available building block 1 was used as starting point for the synthesis of 4DFS (scheme 3). The corresponding dialkoxide was generated using sodium hydride and subsequent careful addition of para‐toluenesulfonyl imidazole (p‐TsIm). This led to selective tosylation at the O‐2 position followed by immediate nucleophilic replacement by the O‐3 alkoxide to give epoxide 2.[ 27 , 28 ] The obtained manno‐epoxide 2 was then opened in a trans‐diaxial fashion with N,N,N,N‐tetrabutylammonium fluoride trihydrate (TBAF×3 H2O) and potassium bifluoride on a gram‐scale to give compound 3 as a single regioisomer. [25] Selective reductive opening of the benzylidene acetal at position 6 was achieved by the protocol described by Shie et al. [29] and subsequent benzylation of the resulting diol gave fully protected altro‐pyranoside 5. The methyl glycoside was then hydrolyzed under acidic conditions [30] to give the corresponding lactol which could be smoothly oxidized to lactone 7 with Dess‐Martin periodinane (DMP). [31] We used Petasis’ reagent as a C1‐elongation method to obtain our desired C7‐sugar.[ 32 , 33 ] The resulting exocyclic enol ether 8 was subsequently dihydroxylated with N‐methylmorpholine‐N‐oxide (NMO) in the presence of catalytic amounts of potassium osmate to give heptulose 9 as a mixture of its α‐anomer in 5 C 2‐conformation and β‐anomer in 2 C 5‐conformation. [34] Final deprotection gave 4DFS as a mixture of its α‐ and β‐furanose and its α‐ and β‐pyranose in a 1.5 : 4 : 4 : 1 ratio as determined by 2D NMR experiments (HMBC and NOESY).
3‐Deoxy‐3‐fluoro‐d‐sedoheptulose was obtained in a similar way: Methyl glucoside 1 again served as starting material (Scheme 4). However, this time 1 was di‐tosylated with para‐toluenesulfonyl chloride (p‐TsCl). [35] Subsequent treatment of intermediate 10 (see Experimental Section) with sodium methoxide [36] led to the formation of the allo‐configured epoxide 11 which was again opened in a trans‐diaxial fashion as described above. In this case, the epoxide opening gave a 4 : 1 mixture of the desired fluorinated sugar 12 and undesired gluco‐configured regioisomer (methyl 4,6‐O‐benzylidene‐3‐deoxy‐3‐fluoro‐α‐d‐gluco‐pyranoside). Altroside 12 then underwent the same benzylidene opening and benzylation protocols as described for 4DFS. Hydrolysis of the methyl glycoside proved to be troublesome in this case and both sulfuric acid and acetic acid led to decomposition of the compound. Strontium chloride in a 1 : 1 mixture of aqueous hydrochloric acid (5 M) and glacial acetic acid [37] finally provided the desired crude lactol which was immediately oxidized with DMP yielding lactone 15. Methylenation, dihydroxylation and hydrogenolysis of the benzyl groups gave 3DFS again as a mixture of its α‐ and β‐ furanose and α‐ and β‐pyranose in a 2.4 : 3 : 4 : 1 ratio, respectively.
First biochemical evaluations
With 3DFS and 4DFS in hand, we wanted to assess whether the fluorinated heptuloses are taken up by cells, then phosphorylated by sedoheptulose kinase (SHPK), and finally whether the fluorine atom halts the enzymatic degradation of the resulting sugar phosphates by TALDO1 and TKT. First uptake studies were conducted with human fibroblasts. The medium of the cells was supplemented with 3DFS, 4DFS or water (control) and incubated for 10 min. After thorough washing, lysis of the cells and removal of macromolecules by centrifugation, the supernatant was evaporated and then subjected to HILIC‐MS analysis. 3DFS and 4DFS were both shown to be taken up by the cells which was verified by mass spectrometry (Figure 1A & B; HILIC‐MS negative mode: m/z 211.0623 [M−H]−, R T=4.74 min (4DFS) and 4.55 min (3DFS)). Both peaks were absent in the control sample (Figure S1, Supporting Information). We then checked for first signs of further metabolism of 4DFS and 3DFS using the same samples and indeed could detect the mass of the corresponding sugar phosphate of 4DFS (Figure 1C, m/z 291.0286 [M‐H]−, R T=9.73 min) while the respective 3DFS phosphate was not found (Figure 1D). The exact three‐dimensional structure of SHPK is still unknown, which makes predictions about its substrate promiscuity difficult. Thus, we conducted an ADP‐accumulation‐based kinase assay to study the phosphorylation of our novel fluorinated sugars by SHPK in more detail. As expected from the cell assays, 3DFS and 4DFS showed very different results. No ATP consumption was detected during the fluorescence‐based SHPK assay with 3DFS. While 4DFS was phosphorylated with no significant difference to the native substrate (d‐sedoheptulose), 3DFS was not accepted by SHPK at all (Figure 2A), suggesting that the OH‐group at position 3 is crucial for kinase activity and cannot be substituted with fluorine. Since phosphorylation is a prerequisite for the anticipated metabolic trapping mechanism, we continued the biochemical evaluation solely with 4DFS. Next, we wanted to see if the C−F bond in 4DFS effectively prevents the enzymatic degradation of the sugar phosphate by TALDO1 and TKT. Thus, in vitro stability assays [38] were conducted. For these, 4DFS or d‐sedoheptulose (control) were enzymatically phosphorylated by SHPK in the presence of either TALDO1 or TKT to test the enzymatic stability of the sugar phosphates. Control experiments clearly show consumption of S7P by both enzymes, while no significant 4DFS phosphate consumption was detected by HILIC‐MS analysis. To our surprise, these experiments clearly demonstrated that phosphorylated 4DFS is neither a substrate for TALDO1 nor for TKT (Figure 2B and C). This makes 4DFS a promising candidate for the development of a new sugar‐based imaging probe relying on the principle of metabolic trapping.
Synthesis of potential radiolabeling precursors for 4DFS
Prompted by these results we set out to synthesize a radiolabeling precursor for 4DFS that allows the late‐stage introduction of fluorine‐18 (t 1/2=110 min; see Supporting Information for details on the synthesis of potential radiolabeling precursors for 3DFS). The synthesis starts with commercially available sedoheptulosan monohydrate which was selectively isopropylidene protected at position 4 and 5 (18, Scheme 5). [39] Acetylation [40] of the free hydroxy groups followed by acidic removal of the acetonide yielded diol 20. [41] Benzylidene protection then yielded 21 [42] and set the stage for oxidative opening of the acetal with sodium bromate and sodium dithionite to give the key intermediate 22. [43] For a radiofluorination of the ‐ now unprotected ‐ position 4 with overall retention of configuration we first had to invert this stereocenter. The best results for this transformation were obtained by a Latrell‐Dax‐epimerization. [44] Unfortunately, the reaction always led to acetate migration from O‐3 to O‐4 to give a 1 : 1 mixture of products 24 a and 24 b. However, we could take advantage of the equilibrium of this migration by separating the unwanted compound 24 a from the desired sugar 24 b and letting 24 a reach the equilibrium state in wet DMF again. Thereby, we were able to push the equilibrium to the side of 24 b. Subsequent chloroacetylation at position 4 gave compound 25 with a suitable orthogonal protecting group now in place. Acetolysis of the 2,7‐anhydro‐bridge with triethylsilyl triflate (TESOTf) in acetic anhydride yielded heptulose 26. [45] Selective removal of the chloroacetate with hydrazine dithiocarbonate (HDTC) gave 27. The excellent yields of all previous transformations allowed us to access this key intermediate on a multigram scale. [46] Installation of various good leaving groups for future radiofluorinations worked smoothly. The reaction with triflic anhydride or nosyl chloride [47] gave the potential radiolabeling precursors 28 a and 28 b, respectively, which will be tested as substrates for late‐stage radiofluorinations in the future.
Conclusions
In summary, the first syntheses of 4‐deoxy‐4‐fluoro‐d‐sedoheptulose (4DFS) and 3‐deoxy‐3‐fluoro‐d‐sedoheptulose (3DFS) were accomplished. Epoxide opening of a pyranoside with TBAF and KHF2 and subsequent C1‐elongation with Petasis’ reagent followed by a dihydroxylation of the double bond were key steps for the synthesis of both sugars. 4DFS and 3DFS were readily taken up by human fibroblasts as seen by HILIC‐MS analysis but only 4DFS was phosphorylated by SHPK. Fluorination at position 4 in d‐sedoheptulose effectively prevented the enzymatic degradation of the corresponding sugar phosphate (4DFS‐7‐phosphate) as verified by in vitro stability assays with SHPK and either TALDO1 or TKT. This makes 4DFS a promising deoxyfluorinated sugar probe for biomedical imaging relying on the principle of metabolic trapping. Ultimately, we have established a synthetic strategy to access two potential precursors (28 a & 28 b) for future synthetic attempts to access [18F]4DFS during radiofluorination experiments.
Experimental Section
General experimental details
1H, 13C and 19F NMR spectra were recorded on either a Bruker AV III HD 700 (1H: 700.40 MHz, 13C: 176.12 MHz, 19F: 659.03 MHz), AV III 600 (1H: 600.25 MHz, 13C: 150.93 MHz, 19F: 564.803 MHz) or AV NEO 500 (1H: 500.32 MHz, 13C: 125.81 MHz) spectrometer. Chemical shifts (δ) are given in parts per million (ppm) and were referenced to (residual) solvent signals as follows: 1H NMR spectra: CDCl3: δH (CHCl3) 7.26, d6 ‐DMSO: δH [(CD2H)SO(CD3)] 2.50, d4 ‐MeOH: δH (CHD2OD) 3.31, and D2O: δH (HDO) 4.79; 13C NMR spectra: CDCl3 (δC 77.16), d6 ‐DMSO (δC 39.52), and d4 ‐MeOH (δC 49.00). 13C NMR spectra in D2O were referenced indirectly to the 1H NMR frequency of the sample using the ”xiref”‐command in Bruker Topspin. External CCl3F (δF 0.00) served as reference for 19F NMR spectra. Coupling constants (J) are reported in Hz. 13C spectra were recorded j‐modulated. The chemical shift of the two parts of AB‐systems are given separately as unweighted mean value of the single signals. “A” is used to denote the down‐field part and “B” to denote the up‐field part of the AB‐system. High resolution mass spectrometry (HRMS) was conducted on a Bruker maXis UHR‐TOF instrument with electrospray ionization (ESI) in the positive ion mode. Optical rotations were measured on a Schmidt‐Haensch Digital Polarimeter Unipol L 2000 and are given in 10‐‐1 deg cm2 g‐1. Chromatographic separations (MPLC) were carried out on a Biotage Isolera Prime (Biotage, Uppsala, Sweden) flash purification system using Macherey–Nagel silica gel 60 (0.04‐0.063 mm) in self‐packed cartridges. Thin layer chromatography (TLC) was carried out on precoated Merck silica gel 60 F254 glass plates or precoated Macherey‐Nagel ALUGRAM Xtra SIL G UV254 aluminum plates. Compounds were visualized with UV light (254 nm) and/or by dipping the plate in one of the following solutions, followed by heating with a heat gun: Cerium ammonium molybdate solution (CAM, 46 g (NH4)6Mo7O24 ×4 H2O, 2 g Ce(SO4)2⋅4H2O) in 1 L 10 %(w/w) aq. H2SO4); KMnO4 solution (9 g KMnO4, 60 g K2CO3 in 900 mL H2O and 15 mL 5 %(w/w) aq. NaOH) or vanillin stain (60 g vanillin in 1 L EtOH and 10 mL conc. H2SO4) followed by heating. 1‐(para‐Toluenesulfonyl)imidazole [48] and Petasis’ reagent [49] were obtained following literature procedures. All other used chemicals and solvents were purchased from commercial sources and used without further purification. Procedures describing the key steps of the synthesis of 4‐deoxy‐4‐fluoro‐d‐sedoheptulose (4DFS) and 3‐deoxy‐3‐fluoro‐d‐sedoheptulose (3DFS) are described below, followed by details on the biochemical evaluation of these compounds. The full synthetic sequence leading to the target compounds, including all analytical data can be found in the Supporting Information to the manuscript.
Additionally, the synthetic details for the preparation of the four potential radiolabeling precursors (28 a and 28 b for the synthesis of [18F]4DFS; and S11 and S13 for the synthesis of [18F]3DFS) are reported in the Supporting Information.
Synthesis of 4‐deoxy‐4‐fluoro‐d–sedoheptulose (4DFS)
Methyl 4‐O‐benzyl‐3‐deoxy‐3‐fluoro‐α‐d–altro‐pyranoside (4) was synthesized following a protocol by Shie et al. [29] Borane THF complex (1 M in THF, 52.0 mL, 51.99 mmol, 5 equiv.) was slowly added to methyl 4,6‐O‐benzylidene‐3‐deoxy‐3‐fluoro‐α‐d‐altro‐pyranoside[ 27 , 28 ] (3, 2.96 g, 10.40 mmol, 1 equiv.) under an argon atmosphere and the reaction mixture was stirred for 10 min at room temperature. Cu(OTf)2 (376 mg, 1.04 mmol, 0.1 equiv.) was added and stirring was continued for 1.5 h. The black suspension was then cooled to 0 °C and triethylamine (1.052 g, 1.45 mL, 1.04 mmol, 1 equiv.) was added dropwise followed by methanol (36 mL). The mixture was warmed to room temperature and co‐evaporated thrice with methanol. The crude residue was purified by MPLC (100 g silica gel, 20–100 % EA in n‐heptane) to obtain methyl 4‐O‐benzyl‐3‐deoxy‐3‐fluoro‐α‐d‐altro‐pyranoside (4) as a colorless oil (2.95 g, 99 %); R f=0.34 (n‐heptane/EA 1 : 3, UV & vanillin); =+106.1 (c=1.0 in CHCl3); 1H NMR (600 MHz, CDCl3) δ=7.38‐7.33 (m, 4H, HAr), 7.33‐7.29 (m, 1H, HAr), 4.86 (dt, 2 J 3,F=49.1 Hz, 3 J 3,2=3 J 3,4=2.9 Hz, 1H, H‐3), 4.73 (d, 2 J H,H=11.7 Hz, 1H, HBn), 4.65 (s, 1H, H‐1), 4.58 (d, 2 J H,H=11.7 Hz, 1H, HBn), 4.09–4.04 (m, 2H, H‐2 & H‐5), 3.84 (ddd, 3 J 4,F=27.2 Hz, 3 J 4,5=9.8 Hz, 3 J 4,3=2.9 Hz, 1H, H‐4), 3.85–3.82 (m, 2H, H‐6a & H‐6b), 3.40 (s, 3H, OCH3), 2.36 (d, 3 J OH,2=7.2 Hz, 1H, OH‐2), 1.97 (dd, 3 J OH,6=6.6 Hz, 3 J OH,6=6.0 Hz, 1H, OH‐6); 13C NMR (151 MHz, CDCl3) δ=137.71 (CAr), 128.69 (2 CHAr), 128.21 (CHAr), 128.14 (2 CHAr), 101.30 (C‐1), 87.03 (d, 1 J 3,F=183.8 Hz, C‐3), 71.54 (CH2 Bn) 70.25 (d, 2 J 4,F=16.8 Hz, C‐4), 68.98 (d, 2 J 2,F=25.3 Hz, C‐2), 67.26 (d, 3 J 5,F=2.9 Hz, C‐5), 62.19 (C‐6), 55.74 (OCH3); 19F{1H} NMR (659 MHz, CDCl3) δ=−207.40 (s); 19F NMR (659 MHz, CDCl3) δ=−207.39 (ddd, 2 J F,3=49.1 Hz, 3 J F,4=27.2 Hz, 3 J F,2=6.5 Hz); HRMS (ESI+): m/z calc. for C14H19FO5Na+ [M+Na]+: 309.1109, found: 309.1115.
Methyl 2,4,6‐tri‐O‐benzyl‐3‐deoxy‐3‐fluoro‐α‐d–altro‐pyranoside (5) Methyl 4‐O‐benzyl‐3‐deoxy‐3‐fluoro‐α‐d‐altro‐pyranoside (4, 2.93 g, 10.22 mmol, 1 equiv.) was dissolved in dry DMF (29.2 mL) under an argon atmosphere and cooled to 0 °C. Sodium hydride (90 % purity, 817 mg, 30.65 mmol, 3 equiv.) was added in small portions and the reaction mixture was stirred for 30 min at 0 °C. Benzyl bromide (5.24 g, 3.6 mL, 30.65 mmol, 3 equiv.) was then added dropwise and the reaction mixture was stirred at room temperature for 16 h. Subsequently, methanol (45 mL) was added at 0 °C, followed by water (45 mL) and EA (45 mL). The biphasic mixture was allowed to come to room temperature, the layers were separated, and the aq. layer was extracted twice with EA. The combined org. layers were washed twice with water and once with brine. The org. layer was dried (MgSO4), filtered and evaporated. The crude residue was purified by MPLC (100 g silica gel, 5–31 % EA in n‐heptane) yielding methyl 2,4,6‐tri‐O‐benzyl‐3‐deoxy‐3‐fluoro‐α‐d‐altro‐pyranoside (5) as a colorless oil (3.824 g, 80 %); R f=0.26 (n‐heptane/EA 4 : 1, UV & CAM); =+47.9 (c=1.0 in CHCl3); 1H NMR (700 MHz, CDCl3) δ=7.36‐7.26 (m, 15H, 15 HAr), 4.79 (dt, 2 J 3,F=49.1 Hz, 3 J 3,2=3.1 Hz, 3 J 3,4=2.7 Hz, 1H, H‐3), 4.74 (s, 1H, H‐1), 4.67 (d, 2 J H,H=12.1 Hz, 1H, HBn), 4.65 (d, 2 J H,H=12.1 Hz, 1H, HBn), 4.61 (d, 2 J H,H=11.6 Hz, 1H, HBn), 4.55 (d, 2 J H,H=11.4 Hz, 1H, HBn), 4.53 (d, 2 J H,H=11.4 Hz, 1H, HBn), 4.51 (d, 2 J H,H=11.6 Hz, 1H, HBn), 4.15 (ddd, 3 J 5,4=9.4 Hz, 3 J 5,6a=4.0 Hz, 3 J 5,6b=2.6 Hz, 1H, H‐5), 3.90 (ddd, 3 J 4,F=27.1 Hz, 3 J 4,5=9.4 Hz, 3 J 4,3=2.7 Hz, 1H, H‐4), 3.78 (dd, 3 J 2,F=7.4 Hz, 3 J 2,3=3.1 Hz, 1H, H‐2), 3.76 (dd, 2 J 6a,6b=10.9 Hz, 3 J 6a,5=4.0 Hz, 1H, H‐6a), 3.73 (dd, 2 J 6b,6a=10.9 Hz, 3 J 6b,5=2.6 Hz, 1H, H‐6b), 3.39 (s, 3H, OCH3); 13C NMR (176 MHz, CDCl3) δ=138.42 (CAr), 137.99 (CAr), 137.57 (CAr), 128.66 (2 CHAr), 128.52 (2 CHAr), 128.46 (2 CHAr), 128.18 (CHAr), 128.09 (2 CHAr), 127.95 (2 CHAr), 127.94 (CHAr), 127.88 (2 CHAr), 127.68 (CHAr), 99.51 (C‐1), 86.56 (d, 1 J 3,F=183.1 Hz, C‐3), 75.74 (d, 2 J 2,F=24.5 Hz, C‐2), 73.65 (CH2 Bn), 72.94 (CH2 Bn), 71.82 (CH2 Bn), 71.41 (d, 2 J 4,F=16.6 Hz, C‐4), 69.34 (C‐6), 67.01 (d, 3 J 5,F=3.8 Hz, C‐5), 55.51 (OCH3); 19F{1H} NMR (659 MHz, CDCl3) δ=−207.65 (s); 19F NMR (659 MHz, CDCl3) δ=−207.65 (ddd, 2 J F,3=49.1 Hz, 3 J F,4=27.1 Hz, 3 J F,2=7.8 Hz); HRMS (ESI+): m/z calc. for C28H31FO5Na+ [M+Na]+: 489.2048, found: 489.2051.
2,4,6‐Tri‐O‐benzyl‐3‐deoxy‐3‐fluoro‐d–altrose (6) was synthesized following a protocol by Matwiejuk et al. [30] Methyl 2,4,6‐tri‐O‐benzyl‐3‐deoxy‐3‐fluoro‐α‐d‐altro‐pyranoside (5, 3.804 g, 8.15 mmol, 1 equiv.) was dissolved in acetic acid (81.5 mL) and 1 M aq. H2SO4 (18.5 mL, 81.53 mmol, 10 equiv.) was added dropwise under stirring. The flask was equipped with a reflux condenser, heated to 100 °C and stirred for 15 h. The reaction mixture was then cooled to room temperature and ice‐cold water (300 mL) was slowly added. The mixture was extracted thrice with CH2Cl2 and the combined org. layers were washed twice with a sat. aq. NaHCO3‐sol. and once with brine. The org. layer was dried (MgSO4), filtered and evaporated. The crude residue was purified by MPLC (100 g silica gel, 0–4 % EA in CH2Cl2) yielding 2,4,6‐tri‐O‐benzyl‐3‐deoxy‐3‐fluoro‐d‐altrose (6) as a colorless oil and as a mixture of anomers (α:β=1 : 4) (1.77 g, 48 %); R f=0.14 (n‐heptane/EA 4 : 1, UV & CAM); =+21.5 (c=1.0 in CHCl3); β‐Pyranose: 1H NMR (600 MHz, CDCl3) δ=7.39‐7.22 (m, 15H, HAr), 5.01 (dt, 3 J 1,OH=11.7 Hz, 3 J 1,2=4 J 1,F=2.0 Hz, 1H, H‐1), 4.74 (ddd, 2 J 3,F=48.7 Hz, 3 J 3,2=4.0 Hz, 3 J 3,4=2.2 Hz, 1H, H‐3), 4.68 (d, 2 J H,H=12.1 Hz, 1H, HBn), 4.64 (d, 2 J H,H=12.1 Hz, 1H, HBn), 4.56 (d, 2 J H,H=12.0 Hz, 1H, HBn), 4.54 (d, 2 J H,H=12.0 Hz, 1H, HBn), 4,47 (s, 2H, CH2 Bn), 3.94 (dd, 3 J 5,4=9.5 Hz, 3 J 5,6=1.5 Hz 1H, H‐5), 3.86 (ddd, 3 J 4,F=29.0 Hz, 3 J 4,5=9.5 Hz, 3 J 4,3=2.2 Hz, 1H, H‐4), 3.77‐3.70 (m, 3H, H‐2, H‐6a & H‐6b), 3.57 (d, 3 J 1,OH=11.7 Hz, 1H, OH); 13C NMR (151 MHz, CDCl3) δ=138.30 (CAr), 137.71 (CAr), 137.23 (CAr), 128.90 (2 CHAr), 128.62 (CHAr), 128.60 (2 CHAr), 128.48 (2 CHAr), 128.30 (2 CHAr), 128.24 (2 CHAr), 128.12 (CHAr), 128.09 (2 CHAr), 127.75 (CHAr), 91.89 (C‐1), 86.77 (d, 1 J 3,F=178.7 Hz, C‐3), 76.05 (d, 2 J 2,F=25.9 Hz, C‐2), 74.10 (CH2 Bn), 73.78 (CH2 Bn), 72.37 (d, 3 J 5,F=3.6 Hz, C‐5), 72.15 (CH2 Bn), 71.20 (d, 2 J 4,F=16.5 Hz, C‐4), 69.15 (C‐6); 19F{1H} NMR (659 MHz, CDCl3) δ=−209.84 (s); 19F NMR (659 MHz, CDCl3) δ=−209.84 (dd, 2 J F,3=48.7 Hz, 3 J F,4=29.1 Hz); α‐Pyranose: 1H NMR (600 MHz, CDCl3) δ=7.38‐7.22 (m, 15H, HAr), 5.20 (d, 3 J 1,OH=7.9 Hz, 1H, H‐1), 4.84 (ddd, 2 J 3,F=49.3 Hz, 3 J 3,2=4.0 Hz, 3 J 3,4=2.6 Hz, 1H, H‐3), 4.68 (d, 2 J H,H=12.1 Hz, 1H, HBn), 4.64 (d, 2 J H,H=12.1 Hz, 1H, HBn), 4.60 (d, 2 J H,H=11.8 Hz, 1H, HBn), 4.56 (d, 2 J H,H=11.8 Hz, 1H, HBn), 4.54 (d, 2 J H,H=12.1 Hz, 1H, HBn), 4.53 (d, 2 J H,H=12.1 Hz, 1H, HBn), 4.28 (dt, 3 J 5,4=8.6 Hz, 3 J 5,6a=3 J 5,6b=4.2 Hz, 1H, H‐5), 3.94 (ddd, 3 J 4,F=27.1 Hz, 3 J 4,5=8.6 Hz, 3 J 4,3=2.6 Hz, 1H, H‐4), 3.82 (ddd, 3 J 2,F=8.0 Hz, 3 J 2,3=4.0 Hz, 3 J 2,1=0.9 Hz, 1H, H‐2), 3.77‐3.69 (m, 2H, H‐6a & H‐6b), 3.27 (dd, 3 J OH,1=7.9 Hz, J OH,F=5.2 Hz, 1H, OH); 13C NMR (151 MHz, CDCl3) δ=138.26 (CAr), 137.68 (CAr), 137.43 (CAr), 128.70 (2 CHAr), 128.62 (CHAr), 128.60 (2 CHAr), 128.50 (2 CHAr), 128.24 (CHAr), 128.17 (2 CHAr), 128.01 (2 CHAr), 127.95 (2 CHAr), 127.77 (CHAr), 93.29 (C‐1), 88.40 (d, 1 J 3,F=179.2 Hz, C‐3), 75.94 (d, 2 J 2,F=22.5 Hz, C‐2), 73.73 (CH2 Bn), 72.80 (CH2 Bn), 72.20 (CH2 Bn), 71.60 (d, 2 J 4,F=16.4 Hz, C‐4), 69.35 (C‐6), 67.80 (d, 3 J 5,F=4.4 Hz, C‐5); 19F{1H} NMR (659 MHz, CDCl3) δ=−205.48 (s); 19F NMR (659 MHz, CDCl3) δ=−205.48 (dddd, 2 J F,3=49.3 Hz, 3 J F,4=27.3 Hz, 3 J F,2=7.0 Hz, J F,OH=5.2 Hz); HRMS (ESI+): m/z calc. for C27H29FO5Na+ [M+Na]+: 475.1891, found: 475.1881.
2,4,6‐Tri‐O‐benzyl‐3‐deoxy‐3‐fluoro‐d–altrono‐1,5‐lactone (7)
2,4,6‐Tri‐O‐benzyl‐3‐deoxy‐3‐fluoro‐d‐altrose (6, 1.745 g, 3.86 mmol, 1 equiv.) was dissolved in dry CH2Cl2 (44.8 mL) under argon. Dess–Martin‐Periodinane (DMP, 3.271 g, 7.99 mmol, 2 equiv.) was added and the mixture was stirred for 1 h at room temperature. Then, the reaction was quenched by the addition of a sat. aq. NaHCO3‐sol. (160 mL) and a sat. aq. Na2S2O3‐sol. (160 mL) was added. The mixture was extracted thrice with CH2Cl2, the combined org. layers were dried (MgSO4), filtered and evaporated. The crude residue was purified by MPLC (100 g silica gel, 4–40 % EA in n‐heptane) yielding 2,4,6‐tri‐O‐benzyl‐3‐deoxy‐3‐fluoro‐d‐altrono‐1,5‐lactone (7) as a colorless oil (1.663 g, 96 %); R f=0.34 (n‐heptane/EA 4 : 1, UV & CAM); =−25.2 (c=1.0 in CHCl3); 1H NMR (600 MHz, CDCl3) δ=7.41‐7.26 (m, 15H, HAr), 5.14 (ddd, 2 J 3,F=49.8 Hz, 3 J 3,2=7.5 Hz, 3 J 3,4=3.1 Hz, 1H, H‐3), 5.04 (d, 2 J H,H=11.5 Hz, 1H, HBn), 4.74 (d, 2 J H,H=11.5 Hz, 1H, HBn), 4.74 (d, 2 J H,H=11.7 Hz, 1H, HBn), 4.62 (d, 2 J H,H=11.7 Hz, 1H, HBn), 4.58 (d, 2 J H,H=11.9 Hz, 1H, HBn), 4.58 (m, 1H, H‐5), 4.48 (d, 2 J H,H=11.9 Hz, 1H, HBn), 4.44 (dd, 3 J 2,F=14.5 Hz, 3 J 2,3=7.5 Hz, 1H, H‐2), 4.17 (ddd, 3 J 4,F=14.0 Hz, 3 J 4,5=4.2 Hz, 3 J 4,3=3.1 Hz, 1H, H‐4), 3.67 (dd, 2 J 6a,6b=11.0 Hz, 3 J 6a,5=3.8 Hz, 1H, H‐6a), 3.64 (dd, 2 J 6b,6a=11.0 Hz, 3 J 6b,5=2.7 Hz, 1H, H‐6b); 13C NMR (151 MHz, CDCl3) δ=168.51 (d, 3 J 1,F=10.4 Hz, C‐1), 137.23 (CAr), 137.16 (2 CAr), 128.71 (2 CHAr), 128.67 (2 CHAr), 128.58 (2 CHAr), 128.39 (2 CHAr), 128.33 (CHAr), 128.19 (CHAr), 128.10 (3 CHAr), 127.90 (2 CHAr), 88.84 (d, 1 J 3,F=186.5 Hz, C‐3), 78.17 (d, 3 J 5,F=6.5 Hz, C‐5), 74.83 (d, 2 J 2,F=24.3 Hz, C‐2), 74.05 (CH2 Bn), 73.94 (CH2 Bn), 73.34 (CH2 Bn), 73.30 (d, 2 J 4,F=17.3 Hz, C‐4), 68.81 (C‐6); 19F{1H} NMR (659 MHz, CDCl3) δ=−199.38 (s); 19F NMR (659 MHz, CDCl3) δ=−199.38 (dt, 2 J F,3=49.8 Hz, 3 J F,2=14.5 Hz, 3 J F,4=14.0 Hz); HRMS (ESI+): m/z calc. for C27H27O5FNa+ [M+Na]+: 473.1735, found: 473.1739.
2,6‐Anhydro‐3,5,7‐tri‐O‐benzyl‐1,4‐dideoxy‐4‐fluoro‐d–altro‐hept‐1‐enitol (8) was synthesized following a protocol by Waschke et al. [32] 2,4,6‐Tri‐O‐benzyl‐3‐deoxy‐3‐fluoro‐d‐altrono‐1,5‐lactone (7, 1.64 g, 3.64 mmol, 1 equiv.) was dissolved in dry toluene (18.2 mL) under an argon atmosphere and the flask was wrapped in aluminum foil. Bis(cyclopentadienyl)dimethyltitanium (S2, 0.5 M in dry toluene, 18.2 mL, 9.10 mmol, 2.5 equiv.) was added dropwise and the flask was equipped with a reflux condenser. The mixture was stirred for 16 h at 70 °C before being cooled to room temperature again. The dark red solution was diluted with n‐heptane (60 mL) and stirring was continued for 30 min. The resulting orange suspension was then filtered through a pad of Celite® and the filtrate was evaporated. The crude residue was purified by MPLC (100 g silica gel, 2–20 % EA in n‐heptane) yielding 2,6‐anhydro‐3,5,7‐tri‐O‐benzyl‐1,4‐dideoxy‐4‐fluoro‐d‐altro‐hept‐1‐enitol (8) as an orange oil (1.215 g, 74 %); R f=0.32 (n‐heptane/EA 9 : 1, UV & CAM); =+48.0 (c 1.0 in CHCl3); 1H NMR (700 MHz, CDCl3) δ=7.36‐7.26 (m, 15H, HAr), 4.95 (s, 1H, H‐1a), 4.91 (ddd, 2 J 4,F=50.6 Hz, 3 J 4,3=4.6 Hz, 3 J 4,5=2.1 Hz, 1H, H‐4), 4.70 (d, 2 J H,H=11.9 Hz, 1H, HBn), 4.69 (d, 2 J H,H=11.9 Hz, 1H, HBn), 4.66 (d, 2 J H,H=11.5 Hz, 1H, HBn), 4.56 (s, 1H, H‐1b), 4.55 (d, 2 J H,H=11.5 Hz, 1H, HBn), 4.54 (d, 2 J H,H=11.6 Hz, 1H, HBn), 4.37 (d, 2 J H,H=11.6 Hz, 1H, HBn), 4.17 (ddd, 3 J 5,F=28.4 Hz, 3 J 5,6=9.5 Hz, 3 J 5,4=2.1 Hz, 1H, H‐5), 4.10 (dd, 3 J 3,F=5.7 Hz, 3 J 3,4=4.6 Hz, 1H, H‐3), 4.06 (ddd, 3 J 6,5=9.5 Hz, 3 J 6,7a=3.7 Hz, 3 J 6,7b=2.5 Hz, 1H, H‐6), 3.82 (dd, 2 J 7a,7b=11.1 Hz, 3 J 7a,6=3.7 Hz, 1H, H‐7a), 3.79 (dd, 2 J 7b,7a=11.1 Hz, 3 J 7b,6=2.5 Hz, 1H); 13C NMR (176 MHz, CDCl3) δ=153.32 (C‐2), 138.38 (CAr), 137.77 (CAr), 137.71 (CAr), 128.57 (2 CHAr), 128.55 (2 CHAr), 128.48 (2 CHAr), 128.10 (2 CHAr), 128.01 (CHAr), 127.95 (2 CHAr), 127.93 (CHAr), 127.88 (2 CHAr), 127.70 (CHAr), 101.91 (C‐1), 87.02 (d, 1 J 4,F=178.1 Hz, C‐4), 76.34 (d, 3 J 6,F=3.0 Hz, C‐6), 75.25 (d, 2 J 3,F=28.6 Hz, C‐3), 73.67 (CH2 Bn), 72.14 (CH2 Bn), 71.16 (d, 2 J 5,F=16.6 Hz, C‐5), 70.06 (CH2 Bn), 69.24 (C‐7); 19F{1H} NMR (659 MHz, CDCl3) δ=−206.16 (s); 19F NMR (659 MHz, CDCl3) δ=−206.16 (ddd, 2 J F,4=50.6 Hz, 3 J F,5=28.4 Hz, 3 J F,3=5.3 Hz); HRMS (ESI+): m/z calc. for C28H29O4FNa+ [M+H2O+Na]+: 471.1942, found: 471.1936.
3,5,7‐Tri‐O‐benzyl‐4‐deoxy‐4‐fluoro‐d–glycero‐d–arabino‐hept‐2‐ulo‐pyranose (9) was synthesized following a protocol by Leshch et al. [34] 2,6‐Anhydro‐3,5,7‐tri‐O‐benzyl‐1,4‐dideoxy‐4‐fluoro‐d‐altro‐hept‐1‐enitol (8, 1.202 g, 2.68 mmol, 1 equiv.) was dissolved in a 4 : 1 (v/v) mixture of acetone and water (53.6 mL) followed by addition of N‐methylmorpholine‐N‐oxide (NMO, 628 mg, 5.36 mmol, 2 equiv.) and potassium osmate dihydrate (49 mg, 0.13 mmol, 0.05 equiv.). The reaction mixture was stirred at room temperature for 16 h, diluted with EA and washed with water and brine. The organic layer was dried (MgSO4), filtered and evaporated. The crude residue was purified by MPLC (100 g silica gel, 12–84 % EA in n‐heptane) yielding 3,5,7‐tri‐O‐benzyl‐4‐deoxy‐4‐fluoro‐d‐glycero‐α/β‐d‐arabino‐hept‐2‐ulopyranose (9) as a brown oil (1.126 g, 87 %); R f=0.28 (n‐heptane/EA 1 : 1, UV & CAM); =+32.4 (c=1.0 in CHCl3); α‐Pyranose ( 5 C 2 ): 1H NMR (700 MHz, CDCl3) δ=7.37‐7.24 (m, 15H, HAr), 4.78 (ddd, 2 J 4,F=49.5 Hz, 3 J 4,3=3.7 Hz, 3 J 4,5=2.5 Hz, 1H, H‐4), 4.65 (d, 2 J H,H=11.9 Hz, 1H, HBn), 4.59 (d, 2 J H,H=11.9 Hz, 1H, HBn), 4.55 (d, 2 J H,H=11.6 Hz, 1H, HBn), 4.53 (d, 2 J H,H=11.6 Hz, 1H, HBn), 4.53 (d, 2 J H,H=11.6 Hz, 1H, HBn), 4.52 (d, 2 J H,H=11.6 Hz, 1H, HBn), 4.25 (ddd, 3 J 6,5=9.8 Hz, 3 J 6,7a=4.4 Hz, 3 J 6,7b=2.1 Hz, 1H, H‐6), 3.90 (ddd, 3 J 5,F=30.1 Hz, 3 J 5,6=9.8 Hz, 3 J 5,4=2.5 Hz, 1H, H‐5), 3.80 (dd, 3 J 3,F=5.7 Hz, 3 J 3,4=3.7 Hz, 1H, H‐3), 3.80 (d, J OH,F=6.9 Hz, 1H, OH‐2), 3.78 (dd, 2 J 7a,7b=11.1 Hz, 3 J 7a,6=4.4 Hz, 1H, H‐7a), 3.71 (dd, 2 J 7b,7a=11.1 Hz, 3 J 7b,6=2.1 Hz, 1H, H‐7b), 3.69 (dd, 2 J 1a,1b=11.1 Hz, 3 J 1a,OH=3.5 Hz, 1H, H‐1a), 3.55 (t, 2 J 1b,1a=3 J 1b,OH=11.1 Hz, 1H, H‐1b), 2.01 (dd, 3 J OH,1b=11.1 Hz, 3 J OH,1a=3.5 Hz, 1H, OH‐1); 13C NMR (176 MHz, CDCl3) δ=138.39 (CAr), 137.75 (CAr), 137.24 (CAr), 128.77 (2 CHAr), 128.61 (2 CHAr), 128.48 (2 CHAr), 128.45 (CHAr), 128.29 (4 CHAr), 128.13 (CHAr), 128.05 (2 CHAr), 127.76 (CHAr), 96.91 (C‐2), 87.22 (d, 1 J 4,F=181.0 Hz, C‐4), 75.35 (d, 2 J 3,F=21.5 Hz, C‐3), 73.77 (CH2 Bn), 73.68 (CH2 Bn), 71.99 (CH2 Bn), 70.81 (d, 2 J 5,F=16.5 Hz, C‐5), 69.21 (C‐7), 67.85 (d, 3 J 6,F=3.4 Hz, C‐6), 65.77 (C‐1); 19F{1H} NMR (659 MHz, CDCl3) δ=−204.33 (s); 19F NMR (659 MHz, CDCl3) δ= −204.33 (ddt, 2 J F,4=49.5 Hz, 3 J F,5=30.1 Hz, 3 J F,3=J F,OH=6.9 Hz); β‐Pyranose ( 2 C 5 ): 1H NMR (700 MHz, CDCl3) δ=7.37‐7.24 (m, 15H, HAr), 5.00 (ddd, 2 J 4,F=49.3 Hz, 3 J 4,3=7.7 Hz, 3 J 4,5=3.2 Hz, 1H, H‐4), 4.80 (d, 2 J H,H=11.0 Hz, 1H, HBn), 4.68 (d, 2 J H,H=11.9 Hz, 1H, HBn), 4.66 (d, 2 J H,H=11.0 Hz, 1H, HBn), 4.62 (d, 2 J H,H=11.9 Hz, 1H, HBn), 4.55 (d, 2 J H,H=12.3 Hz, 1H, HBn), 4.50 (d, 2 J H,H=12.3 Hz, 1H, HBn), 4.15 (dq, 3 J 6,7a=6.2 Hz, 3 J 6,5=3 J 6,7b=4 J 6,F=4.2 Hz, 1H, H‐6), 4.09 (dd, 3 J 3,F=10.1 Hz, 3 J 3,4=7.7 Hz, 1H, H‐3), 4.07 (ddd, 3 J 5,F=14.9 Hz, 3 J 5,6=4.2, 3 J 5,4=3.2 Hz, 1H, H‐5), 3.79 (s, 1H, OH‐2), 3.68 (dd, 2 J 7a,7b=10.4 Hz, 3 J 7a,6=6.2 Hz, 1H, H‐7a), 3.64 (dd, 2 J 7b,7a=10.4 Hz, 3 J 7b,6=4.2 Hz, 1H, H‐7b), 3.58 (dd, 2 J 1a,1b=11.6 Hz, 3 J 1a,OH=7.2 Hz, 1H, H‐1a), 3.57 (dd, 2 J 1b,1a=11.6 Hz, 3 J 1b,OH=6.9 Hz, 1H, H‐1b), 1.96 (t, 3 J OH,1a=7.2 Hz, 3 J OH,1b=6.9 Hz, 1H, OH‐1); 13C NMR (176 MHz, CDCl3) δ=137.96 (CAr), 137.73 (CAr), 137.43 (CAr), 128.72 (2 CHAr), 128.64 (2 CHAr), 128.57 (2 CHAr), 128.56 (2 CHAr), 128.38 (CHAr), 128.03 (CHAr), 128.02 (2 CHAr), 127.99 (CHAr), 127.93 (2 CHAr), 98.25 (d, 3 J 2,F=6.4 Hz, C‐2), 89.76 (d, 1 J 4,F=184.6 Hz, C‐4), 74.87 (d, 4 J C,F=2.1 Hz, CH2 Bn), 74.56 (d, 2 J 3,F=20.0 Hz, C‐3), 74.41 (d, 3 J 6,F=5.8 Hz, C‐6), 74.17 (d, 2 J 5,F=15.8 Hz, C‐5), 73.59 (CH2 Bn), 72.75 (d, 4 J C,F=1.8 Hz, CH2 Bn), 70.29 (C‐7), 65.32 (d, 4 J 1,F=3.4 Hz, C‐1); 19F{1H} NMR (659 MHz, CDCl3) δ=−205.36 (s); 19F NMR (659 MHz, CDCl3) δ=−205.36 (dddd, 2 J F,4=49.3 Hz, 3 J F,5=14.2 Hz, 3 J F,3=10.4, 4 J F,6=4.2 Hz); HRMS (ESI+): m/z calc. for C28H31O6FNa+ [M+Na]+: 505.1997, found: 505.1998.
4‐Deoxy‐4‐fluoro‐d–sedoheptulose (4DFS)
3,5,7‐Tri‐O‐benzyl‐4‐deoxy‐4‐fluoro‐d‐glycero‐α/β‐d‐arabino‐hept‐2‐ulopyranose (9, 170 mg, 0.35 mmol, 1 equiv.) was dissolved in methanol (5 mL) and Pd/C (10 %, 60 mg, 0.04 mmol, 0.1 equiv.) was added. The black suspension was degassed (3 freezing/thawing cycles with liquid N2 under vacuum) and subsequently stirred at room temperature for 24 h (completion of the reaction was verified by absence of aromatic proton signals in d4 ‐methanol after drying a small portion of the reaction mixture in high vacuum). The mixture was filtered, evaporated, and purified by reversed‐phase chromatography (C18‐modified silica gel, H2O) yielding 4‐deoxy‐4‐fluoro‐d‐sedoheptulose (4DFS) as a colorless oil and as a mixture of α‐ and β‐furanoses and α‐ and β‐pyranoses in a 1.5 :4 : 4 : 1 ratio (60 mg, 80 %); R f=0.7 (1‐BuOH/acetone/H2O 5 : 4 : 1, CAM); =+23.4 (c=1.0 in H2O); β‐Furanose: 1H NMR (700 MHz, D2O) δ=5.17 (dt, 2 J 4,F=56.4 Hz, 3 J 4,3=6.1 Hz, 3 J 4,5=5.1 Hz, 1H, H‐4), 4.42 (dd, 3 J 3,F=22.7 Hz, 3 J 3,4=6.1 Hz, 1H, H‐3), 4.00 (ddd, 3 J 5,F=21.4 Hz, 3 J 5,6=7.8 Hz, 3 J 5,4=5.1 Hz, 1H, H‐5), 3.82 (ddd, 3 J 6,5=7.8 Hz, 3 J 6,7b=6.2 Hz, 3 J 6,7a=3.3 Hz, 1H, H‐6), 3.76 (dd, 2 J 7a,7b=11.9 Hz, 3 J 7a,6=3.3 Hz, 1H, H‐7a), 3.62 (dd, 2 J 7b,7a=11.9 Hz, 3 J 7b,6=6.2 Hz, 1H, H‐7b), 3.59 (dd, 2 J 1a,1b=12.1 Hz, 5 J 1a,F=0.7 Hz, 1H, H‐1a), 3.55 (dd, 2 J 1b,1a=12.1 Hz, 5 J 1b,F=1.7 Hz, 1H, H‐1b); 13C NMR (176 MHz, D2O) δ=105.30 (d, 3 J 2,F=10.0 Hz, C‐2), 101.15 (d, 1 J 4,F=182.28 Hz, C‐4), 81.07 (d, 2 J 5,F=24.4 Hz, C‐5), 77.11 (d, 2 J 3,F=22.3 Hz, C‐3), 74.99 (d, 3 J 6,F=3.6 Hz, C‐6), 65.04 (C‐1), 64.94 (C‐7); 19F{1H} NMR (659 MHz, D2O) δ=−192.63 (s); 19F NMR (659 MHz, D2O) δ=−192.63 (dt, 2 J F,4=56.4 Hz, 3 J F,3=3 J F,5=21.4 Hz); α‐Pyranose ( 5 C 2 ): 1H NMR (700 MHz, D2O) δ=4.83 (dt, 2 J 4,F=48.9 Hz, 3 J 4,3=3 J 4,5=3.2 Hz, 1H, H‐4), 4.10 (ddd, 3 J 6,5=10.5 Hz, 3 J 6,7b=5.8 Hz, 3 J 6,7a=2.4 Hz, 1H, H‐6), 4.06 (dd, 3 J 3,F=6.0 Hz, 3 J 3,4=3.2 Hz, 1H, H‐3), 3.88 (ddd, 3 J 5,F=31.1 Hz, 3 J 5,6=10.5 Hz, 3 J 5,4=3.2 Hz, 1H, H‐5), 3.87 (dd, 2 J 7a,7b=12.2 Hz, 3 J 7a,6=2.4 Hz, 1H, H‐7a), 3.75 (dd, 2 J 7b,7a=12.2 Hz, 3 J 7b,6=5.8 Hz, 1H, H‐7b), 3.70 (d, 2 J 1a,1b=11.7 Hz, 1H, H‐1a), 3.53 (d, 2 J 1b,1a=11.7 Hz, 1H, H‐1b); 13C NMR (176 MHz, D2O) δ=99.27 (C‐2), 93.43 (d, 1 J 4,F=179.6 Hz, C‐4), 71.20 (d, 3 J 6,F=2.4 Hz, C‐6), 70.00 (d, 2 J 3,F=23.4 Hz, C‐3), 67.31 (C‐1), 65.67 (d, 2 J 5,F=17.5 Hz, C‐5), 63.76 (C‐7); 19F{1H} NMR (659 MHz, D2O) δ=−202.12 (s); 19F NMR (659 MHz, D2O) δ=−202.12 (ddd, 2 J F,4=48.9 Hz, 3 J F,5=31.1 Hz, 3 J F,3=6.0 Hz); α‐Furanose: 1H NMR (700 MHz, D2O) δ=5.03 (ddd, 2 J 4,F=52.9 Hz, 3 J 4,5=3.8 Hz, 3 J 4,3=2.2 Hz, 1H, H‐4), 4.33 (dd, 3 J 3,F=16.2 Hz, 3 J 3,4=2.2 Hz, 1H, H‐3), 4.24 (ddd, 3 J 5,F=24.0 Hz, 3 J 5,6=6.7 Hz, 3 J 5,4=3.8 Hz, 1H, H‐5), 3.80 (td, 3 J 6,5=3 J 6,7b=6.7 Hz, 3 J 6,7a=3.6 Hz, 1H, H‐6), 3.74 (ddd, 2 J 7a,7b=12.0 Hz, 3 J 7a,6=3.6 Hz, 5 J 7a,F=0.4 Hz, 1H, H‐7a), 3.72 (d, 2 J 1a,1b=12.0 Hz, 1H, H‐1a), 3.66 (d, 2 J 1b,1a=12.0 Hz, 1H, H‐1b), 3.62 (dd, 2 J 7b,7a=12.0 Hz, 3 J 7b,6=6.7 Hz, 1H, H‐7b); 13C NMR (176 MHz, D2O) δ=108.28 (d, 3 J 2,F=4.2 Hz, C‐2), 100.47 (d, 1 J 4,F=183.0 Hz, C‐4), 84.08 (d, 2 J 5,F=25.7 Hz, C‐5), 81.32 (d, 2 J 3,F=23.1 Hz, C‐3), 73.73 (d, 3 J 6,F=5.5 Hz, C‐6), 65.06 (C‐1), 65.02 (C‐7); 19F{1H} NMR (659 MHz, D2O) δ=−182.45 (s); 19F NMR (659 MHz, D2O) δ=−182.45 (ddd, 2 J F,4=52.9 Hz, 3 J F,5=24.0 Hz, 3 J F,3=16.2 Hz); β‐Pyranose ( 2 C 5 ): 1H NMR (700 MHz, D2O) δ=4.93 (ddd, 2 J 4,F=48.9 Hz, 3 J 4,3=8.3 Hz, 3 J 4,5=3.5 Hz, 1H, H‐4), 4.27 (dt, 3 J 5,F=13.8 Hz, 3 J 5,4=3 J 5,6=3.5 Hz, 1H, H‐5), 4.14 (dd, 3 J 3,F=10.9 Hz, 3 J 3,4=8.3 Hz, 1H, H‐3), 3.99 (dddd, 3 J 6,7a=6.3 Hz, 3 J 6,7b=6.0 Hz, 4 J 6,F=4.3 Hz, 3 J 6,5=3.5 Hz, 1H, H‐6), 3.80 (dd, 2 J 7a,7b=12.0 Hz, 3 J 7a,6=6.3 Hz, 1H, H‐7a), 3.77 (dd, 2 J 7b,7a=12.0 Hz, 3 J 7b,6=6.0 Hz, 1H, H‐7b), 3.71 (dd, 2 J 1a,1b=11.9 Hz, 5 J 1a,F=1.0 Hz, 1H, H‐1a), 3.57 (dd, 2 J 1b,1a=11.9 Hz, 5 J 1b,F=1.9 Hz, 1H, H‐1b); 13C NMR (176 MHz, D2O) δ=101.58 (d, 3 J 2,F=6.5 Hz, C‐2), 92.94 (d, 1 J 4,F=178.3 Hz, C‐4), 80.52 (d, 3 J 6,F=5.6 Hz, C‐6), 69.03 (d, 2 J 5,F=16.6 Hz, C‐5), 68.64 (d, 2 J 3,F=20.5 Hz, C‐3), 65.81 (d, 5 J 1,F=3.4 Hz, C‐1), 64.74 (C‐7); 19F{1H} NMR (659 MHz, D2O) δ=−205.02 (s); 19F NMR (659 MHz, D2O) δ=−205.02 (dtd, 2 J F,4=48.9 Hz), 3 J F,5 =13.8 Hz, 3 J F,3=10.9 Hz, 4 J F,6=4.3 Hz); HRMS (ESI+): m/z calc. for C7H13O6FNa+ [M+Na]+: 235.0588, found: 235.0593.
Synthesis of 3‐deoxy‐3‐fluoro‐d–sedoheptulose (3DFS)
Methyl 4‐O‐benzyl‐2‐deoxy‐2‐fluoro‐α‐d–altro‐pyranoside (13 a) & methyl 6‐O‐benzyl‐2‐deoxy‐2‐fluoro‐α‐d–altro‐pyranoside (13 b) were synthesized following a protocol by Shie et al. [29] Methyl 4,6‐O‐benzyliden‐2‐deoxy‐2‐fluoro‐α‐d‐altro‐pyranoside[ 25 , 35 ] (12, 151 mg, 0.53 mmol, 1 equiv.) was dissolved in a borane THF complex solution (1 M in THF, 2.66 mL, 0.04 mmol, 5 equiv.) under argon atmosphere at 0 °C. The resulting mixture was stirred for 10 min before Cu(OTf)2 (9.6 mg, 0.03 mmol, 0.05 equiv.) was added. After 2 h the reaction mixture was cooled to 0 °C and triethylamine (0.08 mL), followed by MeOH (0.95 mL) was added. The solvents were removed in vacuo and the residue was co‐evaporated with methanol. Purification via MPLC (25 g silica gel, 12–100 % EA in n‐heptane) gave the desired product as a clear oily mixture of methyl 4‐O‐benzyl‐2‐deoxy‐2‐fluoro‐α‐d‐altro‐pyranoside (13 a) and methyl 6‐O‐benzyl‐2‐deoxy‐2‐fluoro‐α‐d‐altro‐pyranoside (13 b) in a 1.35 : 1 ratio (141 mg, 93 %); R f=0.24 (n‐heptane/EA 1 : 1, UV & CAM); =+105.2 (c=1.0 in CHCl3); 13 b: 1H NMR (700 MHz, CDCl3) δ=7.38‐7‐28 (m, 5H, HAr), 4.87 (d, 3 J 1,F=9.0 Hz, 1H, H‐1), 4.66 (ddd, 3 J 2,F=44.5 Hz, 3 J 2,3=3.5 Hz, 3 J 2,1=1.6 Hz, 1H, H‐2), 4.63 (s, 2H, HBn), 4.12 (dddd, 3 J 3,F=9.8 Hz, 3 J 3,OH=8.9 Hz, 3 J 3,4=6.5 Hz, 3 J 3,2=3.5 Hz, 1H, H‐3), 3.86 (ddd, 3 J 5,4=8.4 Hz, 3 J 5,6b=5.8 Hz, 3 J 5,6a=2.8 Hz, 1H, H‐5), 3.85 (dd, 2 J 6a,6b =11.5 Hz, 3 J 6a,5 =2.8 Hz, 1H, H‐6a), 3.78 (dddd, 3 J 4,5=8.4 Hz, 3 J 4,OH=8.2 Hz, 3 J 4,3=6.5 Hz, 4 J 4,F=2.3 Hz, 1H, H‐4), 3.77 (dd, 2 J 6b,6a =11.5 Hz, 3 J 6b,5 =5.6 Hz, 1H, H‐6b), 3.47 (s, OCH3), 3.00 (d, 3 J OH,3=8.9 Hz, 1H, OH‐3), 2.68 (d, 3 J OH,4=8.2 Hz, 1H, OH‐4); 13C NMR (176 MHz, CDCl3) δ=137.94 (CAr), 128.42 (2 CHAr), 128.03 (CHAr), 127.63 (2 CHAr), 98.13 (d, 3 J 1,F=31.0 Hz, C‐1), 86.18 (d, 2 J 2,F=175.1 Hz, C‐2), 73.68 (CH2 Bn), 71.38 (d, 3 J 4,F=1.2 Hz, C‐4), 70.29 (C‐6), 67.93 (d, 3 J 3,F=27.3 Hz, C‐3), 67.30 (C‐5), 55.76 (OCH3); 19F {1H} NMR (659 MHz, CDCl3) δ=−196.55 (s); 19F NMR (659 MHz, CDCl3) δ=−196.55 (m); 13 a: 1H NMR (700 MHz, CDCl3) δ=7.38‐7.28 (m, 5H, HAr), 4.82 (d, 3 J 1,F=10.4 Hz, 1H, H‐1), 4.70 (d, 2 J H,H=11.4 Hz, 1H, HBn), 4.66 (ddd, 3 J 2,F=44.5 Hz, 3 J 2,3=3.5 Hz, 3 J 2,1=1.6 Hz, 1H, H‐2), 4.58 (d, 2 J H.H=11.4 Hz, 1H, HBn), 4.28 (dddd, 3 J 3,F=9.8 Hz, 3 J 3,OH=6.5 Hz,3 J 3,4=3.5 Hz, 3 J 3,2=3.5 Hz, 1H, H‐3), 3.95 (ddd, 3 J 4,5=9.9 Hz, 3 J 4,3=3.5 Hz, 4 J 4,F=3.5 Hz, 1H, H‐4), 3.89 (ddd, 2 J 6a,6b=11.7 Hz, 3 J 6a,OH=5.2 Hz, 3 J 6a,5=2.9 Hz, 1H, H‐6a), 3.81 (ddd, 2 J 6b,6a=11.7 Hz, 3 J 6b,OH=7.9 Hz, 3 J 6b,5=4.3 Hz, 1H, H‐6b), 3.81 (ddd, 3 J 5,4=9.9 Hz, 3 J 5,6b=4.3 Hz, 3 J 5,6a=2.9 Hz, 1H, H‐5), 3.44 (s, OCH3), 2.77 (d, 3 J OH,3=6.5 Hz, 1H, OH‐3), 1.87 (dd, 3 J OH,6b=7.9 Hz, 3 J OH,6a=5.2 Hz, 1H, OH‐6); 13C NMR (176 MHz, CDCl3) δ=137.33 (CAr), 128.61 (2 CHAr), 128.18 (CHAr), 127.72 (2 CHAr), 98.49 (d, 3 J 1,F=32.0 Hz, C‐1), 87.08 (d, 2 J 2,F=172.8 Hz, C‐2), 71.44 (CH2 Bn), 66.28 (C‐4), 65.56 (d, 3 J 3,F=27.7 Hz, C‐3), 65.20 (C‐5), 62.28 (C‐6), 55.79 (OCH3); 19F {1H} NMR (700 MHz, CDCl3) δ=−195.55 (s); 19F NMR (700 MHz, CDCl3) δ=−195.55 (m); HRMS (+ESI): m/z calc. for C14H19O5FNa+ [M+Na]+: 309.1109, found: 309.1112.
Methyl 3,4,6‐tri‐O‐benzyl‐2‐deoxy‐2‐fluoro‐α‐d–altro‐pyranoside (14)
Sodium hydride (35.6 mg, 1.49 mmol, 4 equiv.) was suspended in dry THF (1.6 mL) under argon atmosphere and cooled to 0 °C. Stirring was continued for 10 min after addition of a solution of the methyl 4‐O‐benzyl‐2‐deoxy‐2‐fluoro‐α‐d‐altro‐pyranoside and methyl 6‐O‐benzyl‐2‐deoxy‐2‐fluoro‐α‐d‐altro‐pyranoside mixture (13 a & 13 b, 106.3 mg, 0.37 mmol, 1 equiv.) in THF (2.5 mL). Then, benzyl bromide (187 mg, 0.13 mL, 1.49 mmol, 3 equiv.) was added and the resulting mixture was stirred for 10 min at 0 °C followed by 15 h at room temperature. H2O (10 mL) was added, the two layers were separated, and the aqueous layer was extracted with EA (3×10 mL). The crude residue was purified via MPLC (25 g silica gel, 12–100 % EA in n‐heptane) to yield methyl 3,4,6‐tri‐O‐benzyl‐2‐deoxy‐2‐fluoro‐α‐d‐altro‐pyranoside as a colorless oil (14, 148 mg, 86 %); R f=0.78 (n‐heptane/EA 1 : 1, UV & CAM); =+85.7 (c=1.0 in CHCl3); 1H NMR (600 MHz, CDCl3) δ=7.35‐7.21 (m, 15 H, HAr), 4.71 (d, 2 J 1,F=13.3 Hz, 1H, H‐1), 4.71 (d, 2 J H,H=12.4 Hz, 1H, HBn), 4.67 (ddd, 2 J 2,F=45.7 Hz, 3 J 2,3=4.3 Hz, 3 J 2,1=1.3 Hz, 1H, H‐2), 4.65 (d, 2 J H,H=12.4 Hz, 1H, HBn), 4.63 (d, 2 J H,H=12.3 Hz, 1H, HBn), 4.53 (d, 2 J H,H=12.3 Hz, 1H, HBn), 4.52 (d, 2 J H,H=11.8 Hz, 1H, HBn), 4.46 (d, 2 J H,H=11.8 Hz, 1H, HBn), 4.25 (ddd, 3 J 5,4 =8.5 Hz, 3 J 5,6a=4.2 Hz, 3 J 5,6b =2.8 Hz, 1H, H‐5), 3.95 (ddd, 3 J 3,F =8.2 Hz, 3 J 3,2=4.3 Hz, 3 J 3,4 =3.2 Hz, 1H, H‐3), 3.86 (ddd, 3 J 4,5=8.5 Hz, 3 J 4,3=3.2 Hz, 4 J 4,F=3.1 Hz, 1H, H‐4), 3.73 (dd, 2 J 6a,6b =10.8 Hz, 3 J 6a,5 =4.2 Hz, 1H, H‐6a), 3.70 (dd, 2 J 6b,6a=10.8 Hz, 3 J 6b,5=2.8 Hz, 1H, H‐6b), 3.43 (s, OCH3); 13C NMR (151 MHz, CDCl3) δ=138.18 (CAr), 138.06 (CAr), 138.04 (CAr), 128.34 (2 CHAr), 128.31 (2 CHAr), 128.30 (2 CHAr), 127.79 (2 CHAr), 127.78 (2 CHAr), 127.70 (3 CHAr), 127.65 (CHAr), 127.53 (CHAr), 99.34 (d, 3 J 1,F=33.02 Hz, C‐1), 87.89 (d, 2 J 2,F=173.8 Hz, C‐2), 73.50 (CH2 Bn), 72.75 (d, 3 J 3,F=25.17 Hz, C‐3), 72.65 (CH2 Bn), 72.56 (C‐4), 71.83 (CH2 Bn), 69.36 (C‐6), 67.97 (C‐5), 55.61 (OCH3); 19F {1H} NMR (659 MHz, CDCl3) δ=−194.69 (s); 19F NMR (659 MHz, CDCl3) δ=−194.69 (dddd, 2 J F,2=45.7 Hz, 3 J F,1=13.3 Hz, 3 J F,3=8.2 Hz, 4 J F,4=3.1 Hz); HRMS (+ESI): m/z calc. For C28H31O5Fna+ [M+Na]+: 489.2048, found: 489.2045.
3,4,6‐Tri‐O‐benzyl‐2‐deoxy‐2‐fluoro‐α‐d–altrono‐1,5‐lactone (15) was synthesized following a protocol by Shi et al. [37] Methyl 3,4,6‐tri‐O‐benzyl‐2‐deoxy‐2‐fluoro‐α‐d‐altro‐pyranoside (14, 100 mg, 0.214 mmol, 1 equiv.) was dissolved in glacial acetic acid (1.2 mL) and heated to 70 °C. After the addition of 5 M aqueous HCl (0.2 mL) and strontium chloride hexahydrate (5.7 mg, 0.011 mmol, 0.1 equiv.), stirring was continued at 70 °C for 3 h. The reaction mixture was diluted with water (10 mL), extracted with CH2Cl2 (3×15 mL) and washed with a sat. aqueous NaHCO3‐sol. (3×15 mL). The combined organic layers were dried (MgSO4), and the solvent was concentrated in vacuo (25 °C). The crude residue was cooled to 0 °C, DMP (145.08 mg, 0.34 mmol, 1.5 equiv.) was added, and stirring was continued at room temperature for 3 h. The reaction mixture was diluted with CH2Cl2 (10 mL) and washed thrice with a 1 : 1 (v/v) mixture of sat. aqueous NaHCO3/sat. aqueous Na2S2O3‐sol. (15 mL). After drying (MgSO4), the solvent was evaporated and the crude residue was purified by MPLC (25 g silica gel, 5–50 % EA in n‐heptane) to yield 3,4,6‐tri‐O‐benzyl‐2‐deoxy‐2‐fluoro‐α‐d‐altrono‐1,5‐lactone as a colorless oil (15, 50 mg, 52 %); R f=0.70 (n‐heptane/EA 1 : 1, UV & CAM); =−54.2 (c=1.0 in CHCl3); 1H NMR (700 MHz, CDCl3) δ=7.42‐7.16 (m, 15H, HAr), 5.28 (dd, 2 J 2,F=48.2 Hz, 3 J 2,3=9.0 Hz, 1H, H‐2), 4.74 (d, 2 J H,H=12.0 Hz, 2H, HBn), 4.64 (d, 2 J H,H=12.0 Hz, 1H, HBn), 4.58 (d, 2 J H,H=11.9 Hz, 1H, HBn), 4.58 (ddd, 3 J 5,4 =5.9 Hz, 3 J 5,6a=4.6 Hz, 3 J 5,6b =2.7 Hz 1H, H‐5), 4.51 (d, 2 J H,H=11.9 Hz, 1H, HBn), 4.40 (d, 2 J H,H=12.0 Hz, 1H, HBn), 4.34 (ddd, 3 J 3,F=12.0 Hz, 3 J 3,2=9.0 Hz, 3 J 3,4=3.1 Hz, 1H, H‐3), 3.96 (ddd, 3 J 4,5=5.9 Hz, 3 J 4,3=3.1 Hz, 4 J 4,F=3.1 Hz, 1H, H‐4), 3.58 (dd, 2 J 6a,6b =10.8 Hz, 3 J 6a,5 =4.6 Hz, 1H, H‐6a), 3.52 (dd, 2 J 6b,6a=10.8 Hz, 3 J 6b,5=2.7 Hz, 1H, H‐6b); 13C NMR (176 MHz, CDCl3) δ=166.61 (d, 2 J 1,F=20.0 Hz, C‐1), 137.39 (CAr), 137.16 (CAr), 136.92 (CAr), 128.55 (2 CHAr), 128.54 (2 CHAr), 128.50 (2 CHAr), 128.11 (CHAr), 128.04 (2 CHAr), 127.95 (2 CHAr), 127.92 (2 CHAr), 127.69 (2 CHAr), 87.52 (d, 1 J 2,F=189.8 Hz, C‐2), 79.10 (C‐5), 75.13 (d, J 3,F=18.8 Hz, C‐3), 74.63 (d, J 4,F=8.71 Hz, C‐4), 73.76 (CH2 Bn), 73.12 (CH2 Bn), 73.04 (CH2 Bn), 68.97 (C‐6); 19F {1H} NMR (659 MHz, CDCl3) δ=−201.85 (s); 19F NMR (659 MHz, CDCl3) δ=−201.85 (ddd, 2 J F,2=48.2 Hz, 3 J F,3=12.0 Hz, 4 J F,4=3.1 Hz); HRMS (+ESI): m/z calc. for C27H27O5FNa+ [M+Na]+: 473.1735, found: 473.1732.
2,6‐Anhydro‐4,5,7‐tri‐O‐benzyl‐1,3‐dideoxy‐3‐fluoro‐d–altro‐hept‐1‐enitol (16) was synthesized following a protocol by Waschke et al. [32] A 0.5 M solution of Petasis’ reagent (S2, 3.9 mL, 2.2 equiv.) in dry toluene was added under argon atmosphere in the dark to 3,4,6‐tri‐O‐benzyl‐2‐deoxy‐2‐fluoro‐α‐d‐altrono‐1,5‐lactone (15, 400 mg, 0.89 mmol, 1 equiv.) dissolved in dry toluene (1 mL). The mixture was stirred at 65 °C for 16 h before being cooled to room temperature. The solution was diluted with n‐heptane (20 mL) and stirring was continued for 30 min. The resulting orange suspension was then filtered over Celite®, the filtrate evaporated, and the crude residue was purified by MPLC (100 g silica gel, 10–30 % Et2O in n‐heptane+0.5 % Et3N) yielding 2,6‐anhydro‐4,5,7‐tri‐O‐benzyl‐1,3‐dideoxy‐3‐fluoro‐d‐altro‐hept‐1‐enitol as a light yellow oil (16, 255.5 mg, 64 %); R f=0.62 (n‐heptane/Et2O 5 : 1, UV & CAM); =+45.2 (c=0.67 in CHCl3); 1H NMR (600 MHz, CDCl3) δ=7.42–7.16 (m, 15H, HAr), 4.91 (dd, 2 J 3,F=48.5 Hz, 3 J 3,4=5.1 Hz, 1H, H‐3), 4.86 (d, 2 J 1a,1b=5.0 Hz, 1H, H‐1a), 4.72 (d, 2 J H,H=12.3 Hz, 1H, HBn), 4.65 (d, 2 J H,H=12.3 Hz, 1H, HBn), 4.63 (d, 2 J H,H=12.3 Hz, 1H, HBn), 4.61 (d, 2 J 1b,1a=5.0 Hz, 1H, H‐1b), 4.57 (d, 2 J H,H=11.6 Hz, 1H, HBn), 4.54 (d, 2 J H,H=12.3 Hz, 1H, HBn), 4.53 (d, 2 J H,H=11.6 Hz, 1H, HBn), 4.21 (ddd, 3 J 6,5 =8.0 Hz, 3 J 6,7a=4.0 Hz, 3 J 6,7b =3.0 Hz 1H, H‐6), 4.04 (ddd, 3 J 5,6=8.0 Hz, 3 J 5,4=3.0 Hz, 4 J 5,F=3.0 Hz, 1H, H‐5), 3.96 (ddd, 3 J 4,F=8.1 Hz, 3 J 4,3=5.1 Hz, 3 J 4,5=3.0 Hz, 1H, H‐4), 3.76 (dd, 2 J 7a,7b =10.9 Hz, 3 J 7a,6 =4.0 Hz, 1H, H‐7a), 3.71 (dd, 2 J 7b,7a=10.9 Hz, 3 J 7b,6=3.0 Hz, 1H, H‐7b); 13C NMR (151 MHz, CDCl3) δ=153.50 (d, 2 J 2,F=15.0 Hz, C‐2), 138.11 (CAr), 137.89 (CAr), 137.80 (CAr), 128.41 (2 CHAr), 128.40 (2 CHAr), 128.33 (2 CHAr), 127.91 (2 CHAr), 127.85 (CHAr), 127.83 (CHAr), 127.78 (2 CHAr), 127.73 (2 CHAr), 127.60 (CHAr), 100.65 (d, 3 J 1,F=8.9 Hz, C‐1), 87.72 (d, 1 J 3,F=176.5 Hz, C‐3), 76.06 (C‐6), 73.52 (CH2 Bn), 73.04 (d, 2 J 4,F=21.9 Hz, C‐4), 72.94 (CH2 Bn), 72.45 (C‐5), 72.23 (CH2 Bn), 68.98 (C‐7); 19F {1H} NMR (659 MHz, CDCl3) δ=−180.53 (s); 19F NMR (659 MHz, CDCl3) δ=−180.53 (d, 2 J F,3=48.5 Hz); HRMS (+ESI): m/z calc. for C28H29O4FNa+ [M+Na]+: 471.1942, found: 471.1949.
4,5,7‐Tri‐O‐benzyl‐3‐deoxy‐3‐fluoro‐d–glycero‐d–arabino‐hept‐2‐ulopyranose (17) was synthesized following a protocol by Leshch et al. [34] 2,6‐Anhydro‐4,5,7‐tri‐O‐benzyl‐1,3‐dideoxy‐3‐fluoro‐d‐altro‐hept‐1‐enitol (16, 240 mg, 0.54 mmol, 1 equiv.) was dissolved in a 4 : 1 (v/v) mixture of acetone/water (2.6 mL), and the reaction mixture was stirred at rt for 18 h after the addition of potassium osmate dihydrate (9.9 mg, 0.03 mmol, 0.05 equiv.) and NMO (125.4 mg, 1.07 mmol, 2 equiv.). After completion, EA (20 mL) was added, and the mixture was washed with water (2×15 mL). The organic layer was dried (MgSO4), filtered, and evaporated in vacuo. The crude residue was purified by MPLC (10 g silica gel, 12–100 % EA in n‐heptane) yielding 4,5,7‐tri‐O‐benzyl‐3‐deoxy‐3‐fluoro‐d‐glycero‐d‐arabino‐hept‐2‐ulopyranose as an anomeric mixture in a 1:0.1 ratio of its α‐ and β‐pyranose form (β‐pyranose form only interpretable in 19F NMR) as a colorless oil (17, 224 mg, 86 %); R f=0.28 (n‐heptane/EA 1 : 1, CAM); =+41.2 (c=1.0 in CHCl3); α‐Pyranose: 1H NMR (600 MHz, CDCl3) δ=7.46‐7.18 (m, 15H, HAr), 5.38 (s, 1H, OH‐2), 4.86 (d, 2 J H,H=11.8 Hz, 1H, HBn), 4.66 (dd, 2 J 3,F=45.9 Hz, 3 J 3,4=3.8 Hz, 1H, H‐3), 4.67 (d, 2 J H,H=10.5 Hz, 1H, HBn), 4.65 (d, 2 J H,H=10.5 Hz, 1H, HBn), 4.54 (d, 2 J H,H=11.8 Hz, 1H, HBn), 4.53 (s, 2H, HBn), 4.23 (dd, 3 J 5,4=3.4 Hz, 3 J 5,6=9.7 Hz, 1H, H‐5), 4.18 (ddd, 3 J 4,3=3.8 Hz, 3 J 4,5=3.4 Hz, 3 J 4,F=7.0 Hz 1H, H‐4), 3.94 (ddd, 3 J 6,5 =9.7 Hz, 3 J 6,7b =9.9 Hz, 3 J 6,7a=3.2 Hz, 1H, H‐6), 3.84 (dd, 2 J 7a,7b =11.0 Hz, 3 J 7a,6 =3.2 Hz, 1H, H‐7a), 3.72 (dd, 2 J 7b,7a=11.0 Hz, 3 J 7b,6=9.9 Hz, 1H, H‐7b), 3.69 (d, 2 J 1a,1b=10.8 Hz, 1H, H‐1a), 3.54 (dd, 2 J 1b,1a=10.7 Hz, 3 J 1b,OH=10.5 Hz, 1H, H‐1b), 1.93 (d, 3 J OH,1b=10.5 Hz, 1H, OH‐1); 13C NMR (151 MHz, CDCl3) δ=138.27 (CAr), 137.70 (CAr), 136.57 (CAr), 128.72 (2 CHAr), 128.51 (CHAr), 128.49 (2 CHAr), 128.30 (2 CHAr), 128.14 (2 CHAr), 127.96 (CHAr), 127.90 (2 CHAr), 127.83 (2 CHAr), 127.55 (CHAr), 96.10 (d, 2 J 2,F=22.14 Hz, C‐2), 84.27 (d, 1 J 3,F=183.87 Hz, C‐3), 74.73 (CH2 Bn), 73.55 (CH2 Bn), 73.43 (d, 2 J 4,F=26.0 Hz, C‐4), 72.51 (CH2 Bn), 72.09 (C‐6), 68.86 (C‐7), 68.29 (C‐5), 64.29 (d, 3 J 1,F=4.0 Hz, C‐1); 19F {1H} NMR (659 MHz, CDCl3) δ=−195.53 (s); 19F NMR (659 MHz, CDCl3) δ=−195.53 (d, 2 J F,3=45.9 Hz); β‐Pyranose: 19F {1H} NMR (659 MHz, CDCl3) δ=−207.00 (s); 19F NMR (659 MHz, CDCl3) δ=−207.00 (m); HRMS (+ESI): m/z calc. for C28H31O6FNa+ [M+Na]+: 505.1997, found: 505.1993.
3‐Deoxy‐3‐fluoro‐d–sedoheptulose (3DFS)
4,5,7‐Tri‐O‐benzyl‐3‐deoxy‐3‐fluoro‐d‐glycero‐d‐arabino‐hept‐2‐ulopyra‐nose (17, 175 mg, 0.36 mmol, 1 equiv.) was dissolved in methanol (5 mL) and Pd/C (10 % Pd, 85 mg, 0.057 mmol, 0.14 equiv.) was added. The reaction mixture was degassed (3 freezing/thawing cycles with liquid N2 under vacuum) and stirred at room temperature under 1 atm H2 pressure for 24 h. The catalyst was removed by filtration over Celite® and the solvent was removed in vacuo. The crude residue was purified by reversed‐phase chromatography (C18‐modified silica gel, MeCN/H2O 1 : 3) yielding 3‐deoxy‐3‐fluoro‐d‐sedoheptulose as a colorless oil as a mixture of its α‐ and β‐furanoses and α‐ and β‐pyranoses in a 2.4 : 3 : 4 : 1 ratio (3DFS, 64 mg, 84 %); R f=0.72 (1‐BuOH/acetone/H2O 6 : 3 : 1, CAM); =+26.1 (c=1.0 in H2O); β‐Furanose: 1H NMR (700 MHz, D2O) δ=4.97 (dd, 2 J 3,F=52.8 Hz, 3 J 3,4=6.5 Hz, 1H, H‐3), 4.62 (ddd, 3 J 4,F=19.2 Hz, 3 J 4,3=6.5 Hz, 3 J 4,5=6.5 Hz, 1H, H‐4), 3.87 (dddd, 3 J 6,5=6.5 Hz, 3 J 6,7b=6.5 Hz, 3 J 6,7a=3.1 Hz, 5 J 6,F=1.1 Hz, 1H, H‐6), 3.82 (dd, 3 J 5,6=6.5 Hz, 3 J 5,4=6.5 Hz, 1H, H‐5), 3.78 (dd, 2 J 7a,7b=12.0 Hz, 3 J 7a,6=3.1 Hz, 1H, H‐7a), 3.66 (dd, 2 J 1a,1b=12.2 Hz, 4 J 1a,F=1.0 Hz, 1H, H‐1a), 3.64 (dd, 2 J 7b,7a=12.0 Hz, 3 J 7b,6=6.5 Hz, 1H, H‐7b), 3.62 (d, 2 J 1b,1a=12.2 Hz, 1H, H‐1b); 13C NMR (176 MHz, D2O) δ=103.46 (d, 2 J 2,F=17.6 Hz, C‐2), 97.95 (d, 1 J 3,F=194.0 Hz, C‐3), 82.62 (d, 3 J 5,F=9.6 Hz, C‐5), 76.65 (d, 2 J 4,F=22.3 Hz, C‐4), 75.16 (C‐6), 65.48 (C‐1), 64.89 (C‐7); 19F {1H} NMR (659 MHz, CDCl3) δ=−204.94 (s); 19F NMR (659 MHz, CDCl3) δ=−204.94 (dddd, 2 J F,3=52.8 Hz, 3 J F,4=19.2 Hz, 5 J F,6=1.1 Hz, 4 J F,1a=1.0 Hz); α‐Furanose: 1H NMR (700 MHz, D2O) δ=4.89 (dd, 2 J 3,F=50.8 Hz, 3 J 3,4=1.8 Hz, 1H, H‐3), 4.43 (ddd, 3 J 4,F=23.8 Hz, 3 J 4,5=5.2 Hz, 3 J 4,3=1.8 Hz, 1H, H‐4), 4.10 (dd, 3 J 5,6=5.2 Hz, 3 J 5,4=5.2 Hz, 1H, H‐5), 3.89 (ddd, 3 J 6,7b=6.9 Hz, 3 J 6,5=5.2, 3 J 6,7a=3.7 Hz, 1H, H‐6), 3.77 (dd, 2 J 1a,1b=12.2 Hz, 4 J 1a,F=2.6 Hz, 1H, H‐1a), 3.75 (dd, 2 J 7a,7b=12.0 Hz, 3 J 7a,6=3.7 Hz, 1H, H‐7a), 3.68 (dd, 2 J 1b,1a=12.0 Hz, 4 J 1b,F=3.5 Hz, 1H, H‐1b), 3.63 (dd, 2 J 7b,7a=12.2 Hz, 4 J 7b,6=6.9 Hz, 1H, H‐7b); 13C NMR (176 MHz, D2O) δ=107.12 (d, 2 J 2,F=26.5 Hz, C‐2), 102.77 (d, 1 J 3,F=184.4 Hz, C‐3), 86.07 (d, 3 J 5,F=3.4 Hz, C‐5), 77.54 (d, 2 J 4,F=27.2 Hz, C‐4), 73.91 (C‐6), 64.95 (C‐7), 64.65 (d, 3 J 1,F=3.4 Hz, C‐1); 19F {1H} NMR (659 MHz, CDCl3) δ=−193.07 (s); 19F NMR (659 MHz, CDCl3) δ=−193.07 (dddd, 2 J F,3=50.8 Hz, 3 J F,4=23.8 Hz, 4 J F,1b=3.5 Hz, 4 J F,1a=2.6 Hz); β‐Pyranose ( 2 C 5 ): 1H NMR (700 MHz, D2O) δ=4.79 (dd, 2 J 3,F=49.8 Hz, 3 J 3,4=9.3 Hz, 1H, H‐3), 4.31 (ddd, 3 J 4,F=11.7 Hz, 3 J 4,3=9.3 Hz, 3 J 4,5=3.6 Hz, 1H, H‐4), 4.16 (ddd, 3 J 5,4=3.6 Hz, 4 J 5,F=3.6 Hz, 3 J 5,6=2.5 Hz, 1H, H‐5), 4.02 (dddd, 3 J 6,7a=7.2 Hz, 3 J 6,7b=6.3 Hz, 3 J 6,5=2.5, 5 J 6,F=1.1, 1H, H‐6), 3.84 (dd, 2 J 7a,7b=12.0 Hz, 3 J 7a,6=7.2 Hz, 1H, H‐7a), 3.82 (dd, 2 J 7b,7a=12.0 Hz, 4 J 7b,6=6.3 Hz, 1H, H‐7b), 3.71 (dd, 2 J 1a,1b=12.0 Hz, 4 J 1a,F=1.7 Hz, 1H, H‐1a), 3.61 (dd, 2 J 1b,1a=12.0 Hz, 4 J 1b,F=1.1 Hz, 1H, H‐1b); 13C NMR (176 MHz, D2O) δ=99.86 (d, 2 J 2,F=18.5 Hz, C‐2), 90.76 (d, 1 J 3,F=182.2 Hz, C‐3), 81.76 (C‐6), 71.86 (d, 3 J 5,F=7.5 Hz, C‐5), 68.46 (d, 2 J 4,F=19.0 Hz, C‐4), 66.12 (C‐1), 64.82 (C‐7); 19F {1H} NMR (659 MHz, CDCl3) δ=−209.96 (s); 19F NMR (659 MHz, CDCl3) δ=−209.96 (m); α‐Pyranose ( 5 C 2 ): 1H NMR (700 MHz, D2O) δ=4.74 (dd, 2 J 3,F=44.9 Hz, 3 J 3,4=3.8 Hz, 1H, H‐3), 4.28 (ddd, 3 J 4,F=6.4 Hz, 3 J 4,3=3.8 Hz, 3 J 4,5=2.5 Hz, 1H, H‐4), 4.08 (ddd, 3 J 6,5=10.4 Hz, 3 J 6,7b=5.4 Hz, 3 J 6,7a=2.4, 1H, H‐6), 3.88 (dd, 2 J 7a,7b=12.3 Hz, 3 J 7a,6=2.4 Hz, 1H, H‐7a), 3.84 (ddd, 3 J 5,6=10.4 Hz, 4 J 5,F=3.5 Hz, 3 J 5,4=3.5 Hz, 1H, H‐5), 3.80 (dd, 2 J 7b,7a=12.3 Hz, 4 J 7b,6=5.4 Hz, 1H, H‐7b), 3.72 (dd, 2 J 1a,1b=11.9 Hz, 4 J 1a,F=2.5 Hz, 1H, H‐1a), 3.53 (dd, 2 J 1b,1a=11.9 Hz, 4 J 1b,F=3.9 Hz, 1H, H‐1b); 13C NMR (176 MHz, D2O) δ=98.65 (d, 2 J 2,F=24.2 Hz, C‐2), 89.60 (d, 1 J 3,F=176.2 Hz, C‐3), 71.28 (C‐6), 70.37 (d, 2 J 4,F=27.8 Hz, C‐4), 66.36 (3 J 1,F=5.0 Hz, C‐1), 66.22 (d, 3 J 5,F=1.3 Hz, C‐5), 63.62 (C‐7); 19F {1H} NMR (659 MHz, CDCl3) δ=−197.98 (s); 19F NMR (659 MHz, CDCl3) δ=−197.98 (m); HRMS (+ESI): m/z calc. for C7H13O6FNa+ [M+Na]+: 235.0588, found: 235.0586.
Biochemical assays
HILIC‐MS analysis
All solvents were of MS‐grade. Water and MeCN were purchased from Honeywell (Seelze, Germany). Concentrated formic acid was obtained from VWR (Radnor, Pennsylvania, USA) and ammonium bicarbonate as well as ammonium hydroxide from Sigma Aldrich (St. Louis, Missouri, USA). Hydrophilic interaction liquid chromatography (HILIC) was performed using an Atlantis Premier BEH Z‐HILIC Column (2.1 mm×150 mm; 1.7 μm) (Waters, Milford, MA, USA) on a Vanquish Horizon HPLC system (Thermo Fisher Scientific, Waltham, MA, USA). Mobile phase A consisted of 15 mM ammonium bicarbonate in water (pH=9.00), and mobile phase B of 15 mM ammonium bicarbonate in a 9 : 1 mixture (v/v) of MeCN & H2O (pH=9.00). The separation was achieved using a 15 min gradient as follows: the start conditions were 100 % B with a gradient to 85 % B at 2 min, followed by an isocratic elution at 85 % until 7 min, from 7–10 min a ramp to 40 % B was applied, and then an isocratic elution at 40 % B from 10–11 min followed. The system was re‐equilibrated using 100 % B from 11–15 min. The column temperature was 30 °C and the flow rate 250 μL/min throughout the chromatographic run. Mass spectrometry analysis was performed on Thermo Scientific™ Orbitrap ID‐X™ Tribrid™ mass spectrometer with an electrospray ionization (ESI) in the negative ion mode. ESI source parameters were set as follows: spray voltage 2900 V, sheath gas 40, auxiliary gas 8, ion transfer tube temperature 275 °C. An MS full scan was conducted in a range of 200–600 m/z at a resolution of 60 000. Chromatographic data was analyzed with FreeStyleTM.
Cellular uptake assays
An aqueous solution of sugar (3DFS or 4DFS, 0.1 M) was added to adherent human dermal fibroblasts cultured in DMEM medium containing 10 % FBS to a final concentration of 1 mM for the respective sugar. No fluorinated sugar was added to the control sample. Cells were incubated at 37 °C for 10 min, then the culture medium was removed, and cells were thoroughly washed (3×5 mL water). The cells were shock‐frozen with liquid nitrogen in the plates and stored at −80 °C. Directly before HILIC‐MS analysis, the cells were taken from the freezer and instantly lysed by the addition of an 8 : 2 (v/v) mixture of methanol and water (300 μL), scraped off the plates and transferred to an Eppendorf tube. The suspension was centrifuged (18 000 g, 20 min, 12 °C) to clear from precipitates. The supernatant was then collected and evaporated at 45 °C with a SpeedVacTM. The remaining small molecule extract was dissolved in a mixture of MeCN/H2O (1 : 1 (v/v), 160 μL) and subjected to HILIC‐MS‐analysis.
Kinase assays
Recombinant sedoheptulose kinase (SHPK) was expressed in E.coli and purified as previously described. [5] ADP‐QuestTM Assay kit was obtained from DisoverX and used according to the manufacturer‘s instructions. In short: 20 μL SHPK (0.009 μg/μL in assay buffer), 10 μL sugar solution (d‐sedoheptulose, 3DFS or 4DFS; 10 mM in water), 20 μL reagent A, 40 μL reagent B and 10 μL ATP solution (2 mM in 10 mM HEPES pH 7.6) were mixed in a 96 well plate. Fluorescence was measured on a BioTek Synergy 2 plate reader (excitation wavelength: 530 nm, emission wavelength: 590 nm) for 10 min (signal read‐out every 2 min). All experiments were performed in triplicates. RFU mean of negative control (sedoheptulose with no ATP added) was subtracted from all other values for analysis. The shown graph (Figure 2A) represents the change in signal from starting‐ to endpoint compared to the positive control (sedo) which was normalized to 100 %. Data analysis was done with GraphPad Prism.
Stability assays [38]
Human transaldolase (TALDO1) was purchased from ProSpecBio (Rehovot, Israel) and used as received. Transaldolase stability assays contained the following components in water: 1 mM sugar (sedo or 4DFS), 1 mM ATP, 10 mM HEPES pH 7.6, 20 mM KCl, 10 mM MgCl2, 1 mM G3P, 0.045 μg SHPK & 1 μg TALDO1 in a final volume of 25 μL. The reactions were incubated at 30 °C for 1.5 h, then diluted 1 : 100 with MeCN/water 1 : 1 (v/v) and subjected to HILIC‐MS analysis. The shown graph represents the peak area of the respective sugar phosphate compared to the negative control (no TALDO1 added) which was normalized to 100 % (Figure 2B). All experiments were performed in triplicates. Statistical analysis was done with GraphPad PrismTM.
Human transketolase (TKT) was purchased from ProSpecBio (Rehovot, Israel) and used as received. Transketolase stability assays contained the following components in water: 1 mM sugar (sedo or 4DFS), 1 mM ATP, 10 mM HEPES pH 7.6, 20 mM KCl, 10 mM MgCl2, 1 mM G3P, 0.5 mM ThPP, 0.045 μg SHPK & 1 μg TKT in a final volume of 25 μL. The reactions were incubated at 30 °C for 0.5 h, then diluted 1 : 100 with MeCN/water 1 : 1 (v/v) and subjected to HILIC‐MS analysis. The shown graph represents the peak area of the respective sugar phosphate compared to the negative control (no TKT added) which was normalized to 100 % (Figure 2C). All experiments were performed in triplicates. Statistical analysis was done with GraphPad PrismTM.
Supporting Information
All experimental procedures, NMR spectra and chromatograms can be found in the Supporting Information. The authors have cited additional references within the Supporting Information. [50]
Author Contributions
L.S., T.S. & K.P. conceived the synthetic routes and wrote the original draft of the manuscript. L.S. & T.S. synthesized all compounds. L.S., T.S. & A.H. conducted biochemical experiments and assays. M.P. performed HILIC‐MS analysis. E.R. supervised HILIC‐MS analysis. H.K. performed NMR analysis of final carbohydrates. K.P., M.M. & A.H. conceived the project. K.P. & A.H. supervised the project. K.P. acquired funding for the project. L.S., T.S., M.P., H.K., T.B., E.P., M.M., A.H. & K.P. reviewed and edited the manuscript.
Conflict of interest
The authors declare no conflict of interest.
Supporting information
Acknowledgments
We gratefully acknowledge the financial support by the Austrian Science Fund (FWF): P32421‐N28. Furthermore, we thank the NMR center and the mass spectrometry center of the Faculty of Chemistry (University of Vienna).
Scheibelberger L., Stankovic T., Pühringer M., Kählig H., Balber T., Patronas E.-M., Rampler E., Mitterhauser M., Haschemi A., Pallitsch K., Chem. Eur. J. 2023, 29, e202302277.
References
- 1. Rahman M., Hasan M. R., Adv. Mater. Res. 2014, 995, 1–27. [Google Scholar]
- 2. Jiang P., Du W., Wu M., Protein Cell 2014, 5, 592–602. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Touchman J., Anikster Y., Dietrich N., Maduro V., McDowell G., Shotelersuk V., Bouffard G., Beckstrom-Sternberg S., Gahl W., Green E., Genome Res. 2000, 10, 165–173. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Wamelink M. M. C., Struys E. A., Jansen E. E. W., Levtchenko E. N., Zijlstra F. S. M., Engelke U., Blom H. J., Jakobs C., Wevers R. A., Hum. Mutat. 2008, 29, 532–536. [DOI] [PubMed] [Google Scholar]
- 5. Haschemi A., Kosma P., Gille L., Evans C. R., Burant C. F., Starkl P., Knapp B., Haas R., Schmid J. A., Jandl C., Amir S., Lubec G., Park J., Esterbauer H., Bilban M., Brizuela L., Pospisilik J. A., Otterbein L. E., Wagner O., Cell Metab. 2012, 15, 813–826. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Kardon T., Stroobant V., Veiga-da-Cunha M., Schaftingen E. V., FEBS Lett. 2008, 582, 3330–3334. [DOI] [PubMed] [Google Scholar]
- 7. Nagy C., Haschemi A., Biochem. Soc. Trans. 2013, 41, 674–680. [DOI] [PubMed] [Google Scholar]
- 8. Compagno M., Lim W. K., Grunn A., Nandula S. V., Brahmachary M., Shen Q., Bertoni F., Ponzoni M., Scandurra M., Califano A., Bhagat G., Chadburn A., Dalla-Favera R., Pasqualucci L., Nature 2009, 459, 717–721. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Quade B. J., Wang T.-Y., Sornberger K., Cin P. D., Mutter G. L., Morton C. C., Genes Chromosomes Cancer 2004, 40, 97–108. [DOI] [PubMed] [Google Scholar]
- 10. Stearman R. S., Dwyer-Nield L., Zerbe L., Blaine S. A., Chan Z., Bunn P. A., Johnson G. L., Hirsch F. R., Merrick D. T., Franklin W. A., Baron A. E., Keith R. L., Nemenoff R. A., Malkinson A. M., Geraci M. W., Am. J. Pathol. 2005, 167, 1763–1775. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Langbein S., Frederiks W. M., Zur Hausen A., Popa J., Lehmann J., Weiss C., Alken P., Coy J. F., Int. J. Cancer 2008, 122, 2422–2428. [DOI] [PubMed] [Google Scholar]
- 12. Ying H., Dey P., Yao W., Kimmelman A. C., Draetta G. F., Maitra A., DePinho R. A., Genes Dev. 2016, 30, 355–385. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Forbes N. S., Meadows A. L., Clark D. S., Blanch H. W., Metab. Eng. 2006, 8, 639–652. [DOI] [PubMed] [Google Scholar]
- 14. Sun W., Liu Y., Glazer C. A., Shao C., Bhan S., Demokan S., Zhao M., Rudek M. A., Ha P. K., Califano J. A., Clin. Cancer Res. 2010, 16, 857–866. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Zhang S., Yang J.-H., Guo C.-K., Cai P., Cancer Lett. 2007, 253, 108–114. [DOI] [PubMed] [Google Scholar]
- 16. Chen E. I., Hewel J., Krueger J. S., Tiraby C., Weber M. R., Kralli A., Becker K., Yates J. R., Felding-Habermann B., Cancer Res. 2007, 67, 1472–1486. [DOI] [PubMed] [Google Scholar]
- 17. Hu L.-H., Yang J.-H., Zhang D.-T., Zhang S., Wang L., Cai P.-C., Zheng J.-F., Huang J.-S., Anti-Cancer Drugs 2007, 18, 427–433. [DOI] [PubMed] [Google Scholar]
- 18. Patra K. C., Hay N., Trends Biochem. Sci. 2014, 39, 347–354. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Gallagher B. M., Fowler J. S., Gutterson N. I., MacGregor R. R., Wan C.-N., Wolf A. P., J. Nucl. Med. 1978, 19, 1154–1161. [PubMed] [Google Scholar]
- 20. Linclau B., Ardá A., Reichardt N.-C., Sollogoub M., Unione L., Vincent S. P., Jiménez-Barbero J., Chem. Soc. Rev. 2020, 49, 3863–3888. [DOI] [PubMed] [Google Scholar]
- 21. Omami G., Tamimi D., Branstetter B. F., Imaging Sci. Dent. 2014, 44, 325–332. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Evdokimov N. M., Clark P. M., Flores G., Chai T., Faull K. F., Phelps M. E., Witte O. N., Jung M. E., J. Med. Chem. 2015, 58, 5538–5547. [DOI] [PubMed] [Google Scholar]
- 23. Zhang M., Chen H.-W., Liu Q.-Q., Gao F.-T., Li Y.-X., Hu X.-G., Yu C.-Y., J. Org. Chem. 2022, 87, 1272–1284. [DOI] [PubMed] [Google Scholar]
- 24. Dostie S., Prévost M., Mochirian P., Tanveer K., Andrella N., Rostami A., Tambutet G., Guindon Y., J. Org. Chem. 2016, 81, 10769–10790. [DOI] [PubMed] [Google Scholar]
- 25. Yan N., Lei Z.-W., Su J.-K., Liao W.-L., Hu X.-G., Chin. Chem. Lett. 2017, 28, 467–470. [Google Scholar]
- 26. Waschke D., Thimm J., Thiem J., Org. Lett. 2011, 13, 3628–3631. [DOI] [PubMed] [Google Scholar]
- 27. Hicks D. R., Fraser-Reid B., Synthesis 1974, 1974, 203–203. [Google Scholar]
- 28. Comba M. B., Mangione M. I., Suárez A. G., Sarotti A. M., Spanevello R. A., Eur. J. Org. Chem. 2018, 2018, 6848–6856. [Google Scholar]
- 29. Shie C.-R., Tzeng Z.-H., Kulkarni S. S., Uang B.-J., Hsu C.-Y., Hung S.-C., Angew. Chem. Int. Ed. 2005, 44, 1665–1668. [DOI] [PubMed] [Google Scholar]
- 30. Matwiejuk M., Thiem J., Eur. J. Org. Chem. 2011, 2011, 5860–5878. [Google Scholar]
- 31. Dess D. B., Martin J. C., J. Org. Chem. 1983, 48, 4155–4156. [Google Scholar]
- 32. Waschke D., Leshch Y., Thimm J., Himmelreich U., Thiem J., Eur. J. Org. Chem. 2012, 2012, 948–959. [Google Scholar]
- 33. Petasis N. A., Bzowej E. I., J. Am. Chem. Soc. 1990, 112, 6392–6394. [Google Scholar]
- 34. Leshch Y., Jacobsen A., Thimm J., Thiem J., Org. Lett. 2013, 15, 4948–4951. [DOI] [PubMed] [Google Scholar]
- 35. Hofferberth M. L., Brückner R., Angew. Chem. Int. Ed. 2014, 53, 7328–7334. [DOI] [PubMed] [Google Scholar]
- 36. Venkatesham A., Kachare D., Schepers G., Rozenski J., Froeyen M., Van Aerschot A., Molecules 2015, 20, 4020–4041. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Shi Y.-H., Xie Y.-F., Liu Y.-Q., Wei Q.-C., Xu W.-R., Tang L.-D., Zhao G.-L., Chin. Chem. Lett. 2014, 25, 561–566. [Google Scholar]
- 38. Clark P. M., Flores G., Evdokimov N. M., McCracken M. N., Chai T., Nair-Gill E., O'Mahony F., Beaven S. W., Faull K. F., Phelps M. E., Jung M. E., Witte O. N., Proc. Natl. Acad. Sci. USA 2014, 111, E2866-E2874. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Haskins W. T., Hann R. M., Hudson C. S., J. Am. Chem. Soc. 1952, 74, 2198–2200. [Google Scholar]
- 40. Heyns K., Soldat W., Köll P., Chem. Ber. 1973, 106, 1668–1677. [Google Scholar]
- 41. Köll P., Schultek T., Chem. Ber. 1977, 110, 1994–2004. [Google Scholar]
- 42. Heyns K., Neste H., Thiem J., Chem. Ber. 1981, 114, 891–908. [Google Scholar]
- 43. Adinolfi M., Barone G., Guariniello L., Iadonisi A., Tetrahedron Lett. 1999, 40, 8439–8441. [Google Scholar]
- 44. Albert R., Dax K., Link R. W., Stütz A. E., Carbohydr. Res. 1983, 118, C5-C6. [Google Scholar]
- 45. Zottola M., Rao B. V., Fraser-Reid B., J. Chem. Soc. Chem. Commun. 1991, 969. [Google Scholar]
- 46. Van Boeckel C. A. A., Beetz T., Tetrahedron Lett. 1983, 24, 3775–3778. [Google Scholar]
- 47. Chiotellis A., Sladojevich F., Mu L., Müller Herde A., Valverde I. E., Tolmachev V., Schibli R., Ametamey S. M., Mindt T. L., Chem. Commun. 2016, 52, 6083–6086. [DOI] [PubMed] [Google Scholar]
- 48. Loukou C., Changenet-Barret P., Rager M.-N., Plaza P., Martin M. M., Mallet J.-M., Org. Biomol. Chem. 2011, 9, 2209. [DOI] [PubMed] [Google Scholar]
- 49. Csuk R., Glänzer B. I., Tetrahedron 1991, 47, 1655–1664. [Google Scholar]
- 50. Rauter A. P., Oliveira O., Canda T., Leroi E., Ferreira H., Ferreira M. J., Ascenso J. A., J. Carbohydr. Chem. 2002, 21, 257–273. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.